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ABSTRACT 
The a-tocopherol transfer protein (a-TTP) is responsible for the retention of the a-
tocopherol form of vitamin E in living organisms. The detailed ligand transfer 
mechanism by a-TTP is still yet to be fully elucidated. To date, studies show that a-TTP 
transfers a-tocopherol from late endosomes in liver cells to the plasma membrane where 
it is repackaged into very low density lipoprotein (VLDL) and released into the 
circulation. 
Late endosomes have been shown to contain a lipid known as lysobisphosphatidic 
acid (LBP A) that is unique to this cellular compartment. LBPA plays a role in 
intracellular trafficking and controlling membrane curvature. Taking these observations 
into account plus the fact that certain proteins are recruited to membranes based on 
membrane curvature, the specific aim of this project was to examine the effect of LBP A 
on a-TTP binding to lipid membranes. To achieve this objective, dual polarization 
interferometry (DPI) and a vesicle binding assay were employed. Whilst DPI allows 
protein binding affinity to be measured on a flat lipid surface, the vesicle binding assay 
determines protein binding affinity to lipid vesicles mimicking curved membranes. 
DPI analysis revealed that the amount of a-TTP bound to lipid membranes is 
higher when LBPA is present. Using the vesicle binding assay, a similar result was seen 
where a greater amount of protein is bound to large unilamellar vesicles (LUV s) 
containing LBP A. However, the effect of LBP A was attenuated when small unilamellar 
vesicles (SUVs) were replaced with LUVs. The outcome of this project suggests that a-
TTP binding to membranes is influenced by membrane curvature, which in turn is 
induced by the presence of LBP A. 
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1. INTRODUCTION 
1.1 Vitamin E: Structure and Function 
Vitamin E refers to eight lipid-soluble molecules which can be grouped into 
two classes, tocopherols and tocotrienols. The general structure of vitamin E consists 
of a chromanol head group and an isoprenoid derived side chain [1]. Tocopherols and 
tocotrienols differ in the degree of saturation of the side chain. The tocopherols have 
a saturated chain giving rise to three chiral centres at C2, C4' and C8' [1]. As a result, 
eight stereoisomers are present in synthetic racemic vitamin E known as all rac-a-
tocopherol. Only the RRR-a-tocopherol corresponds to the naturally occurring form 
[1-2]. The tocotrienols, on the other hand, have double bonds at C3', CT and Cll' 
and a chiral centre at C2. The nomenclature of vitamin E is based on the methylation 
pattern of the chromanol head group which gives rise to a-, p-, y- and o-tocopherol 
and tocotrienol as shown in Figure 1 [3]. Amongst the eight naturally occurring 
forms of vitamin E, a-tocopherol has the highest biological activity [3, 4]. 
HO 
tocopherol 
HO 
C~ tocotrienol 
C~ 
C~ 
CH3 
CH3 
H 
H 
CH3 
H 
CH3 
H 
Figure 1: Structure of tocopherols and tocotrienols. Taken from Azzi and Stocker 
[3]. 
1 
Since its discovery in 1922 by Evans and Bishop as a factor required for 
normal reproduction [5], vitamin E's most established role to date is its function as an 
antioxidant, protecting polyunsaturated fatty acids (PUF As) in cell membranes against 
free radical damage [6-7] . A free radical is any species existing independently with 
one or more unpaired electrons making it highly reactive and causing it to attack 
biological molecules such as DNA, proteins and lipids (8]. 
Free radical attack on unsaturated lipids initiates lipid peroxidation; the 
process of oxidative degeneration of lipids which occurs as a chain reaction in three 
stages [9]. The first stage, which is known as the initiation phase, involves the 
generation of a carbon-centred radical (R-). This is usually the result of other free 
radicals such as hydroxyl (OH-) radicals attacking PUFAs via the abstraction of a 
hydrogen atom from the bis-allylic methylene between two double bonds [10]. Next 
is the propagation phase, which involves the production of the peroxyl radical 
(ROO-) when the carbon-centred radical reacts with molecular oxygen. The peroxyl 
radical formed is then capable of further propagating the chain reaction by abstracting 
another H-atom from a neighbouring PUFA, forming a hydroperoxide (ROOH) and a 
new carbon-centred radical [10]. A single initiation event is capable, in theory, of 
destroying hundreds of lipid molecules. Consequently the PUF As that are consumed 
disrupt membrane structure and function, eventually affecting cell integrity [11]. 
Vitamin E, specifically a-tocopherol (a-TO-H), acts as a chain-breaking 
antioxidant by inhibiting the propagation phase of lipid peroxidation [10]. The 
hydrogen atom of the phenol on the chromanol ring is donated to the peroxyl radical 
resulting in the formation of a less reactive tocopheroxyl radical (a-TO-) [12]. The 
tocopheroxyl radical can then be reduced by glutathione, ascorbate or ubiquinol to 
2 
regenerate tocopherol [4, 13]. Figure 2 illustrates the role of vitamin E in lipid 
peroxidation. 
EI 
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Figure 2: The role of a-tocopherol as a chain-breaking antioxidant in lipid 
peroxidation. A carbon-centred free radical from the hydrogen abstraction of 
PUF As reacts with molecular oxygen to form a peroxyl radical. Donation of the 
phenolic hydrogen from a-tocopherol leads to the formation of hydro peroxide and a 
tocopheroxyl radical. The tocopheroxyl radical is regenerated to a-tocopherol 
through reduction by ascorbate and glutathione. Takenfrom Burton and Traber [10]. 
Taking into account the significant role of vitamin E in maintaining cell 
membrane integrity and its occurrence in hydrophobic domains such as lipoproteins 
and cell membranes, many studies have been performed to determine its exact 
localization [14]. While the precise location of the chromanol ring within cell 
membranes has not been fully determined, the general position of vitamin E within 
membranes can be described as follows [IS]. The side chain of vitamin E is oriented 
towards the hydrophobic core of membranes, facilitating its incorporation and 
retention in membranes, while the chromanol ring, primarily responsible for its 
3 
antioxidant activity, is located among the polar head groups [4, 14-15]. This is 
brought about by the amphiphilic nature of vitamin E due to its polar hydroxyl 
substituent on the chromanol ring and the greasy hydrophobic tail [14]. 
1.2 Vitamin E: Absorption and Delivery 
One of the requirements for a compound to be classified as a vitamin is that it 
must be essential for human health [16]. Vitamin E is obtained from the diet. 
Vegetable oils, such as sunflower oil are the main sources of vitamin E in the human 
diet [6]. Since vitamin E is hydrophobic in nature, lipoproteins are its main transport 
system to tissues in the body [17]. Upon ingestion, vitamin E is absorbed in the small 
intestine with other lipid compounds and packaged into chylomicrons. It then enters 
the systemic circulation via the lymphatic system [18]. Following that, chylomicrons 
undergo transformation to chylomicron remnants by the action of lipoprotein lipase 
(LPL). As a result, a portion of the vitamin E is absorbed by surrounding tissues [17], 
while the rest is retained in chylomicron remnants and delivered to the liver. The 
chylomicron remnants are absorbed into liver cells via receptor-mediated endocytosis 
[17]. Vitamin E is then repackaged in liver cells, and secreted into the plasma in very 
low density lipoproteins (VLDLs). The vitamin E in VLDLs can either then be 
transferred to high density lipoproteins (HDLs) via lipolysis or to low density 
lipoproteins (LDLs) through the conversion ofVLDLs [17]. 
However, it was discovered that only the RRR-a-tocopherol form of vitamin E 
is present in nascent VLDLs [19], while the remaining forms of vitamin E were found 
to be excreted in the bile [20]. Nearly two decades of investigation showed that a 
protein, known as a-tocopherol transfer protein (a-TTP) is responsible for this 
selective retention [21-25]. This is supported by its high binding affinity with a-
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tocopherol in comparison with the other forms of vitamin E [26,27] and also a-TTP's 
capability to transport a-tocopherol between liposomes [22,23]. 
1.3 u-Tocopherol Transfer Protein (u-TTP) 
a-TTP is a cytosolic protein, first isolated from rat liver [28]. Later, it was 
isolated from human liver [29] and found to have 94 % homology to rat a-TTP [30]. 
Though a-TTP is mainly expressed in the liver, it is also expressed in the brain, lung 
and kidney, but at much lower levels [20]. a-TTP has a molecular weight of about 32 
kDa and is comprised of 278 amino acids [30]. It belongs to the CRAL-TRIO protein 
family, whose members contain the CRAL-TRIO domain, a lipid binding domain 
composed of an amino-terminal three-helix coil, and a larger C-terminal domain [31]. 
The CRAL-TRIO domain obtained its name from the cellular retinaldehyde-binding 
protein (CRALBP) and the Trio protein, a guanine exchange factor [27]. 
The significance of a-TTP in the regulation of vitamin E plasma levels was 
made clear when it was discovered that mutations in the ttpA gene resulted in very 
low plasma a-tocopherol levels and a neurological disorder termed ataxia with 
vitamin E deficiency (AVED) [32]. Similar symptoms were also observed in a-TTP 
knock-out mice [33]. In addition, a-TTP has also shown the ability to transfer a-
tocopherol between liposomes and micro somes [22] and facilitate the secretion of a-
tocopherol in cultured liver cells [34]. These observations further provide evidence 
supporting the role of a-TTP in a-tocopherol retention in the body. 
The underlying mechanism of intermembrane tocopherol transfer by a-TTP is 
still not fully understood, however, its three-dimensional structure has given further 
insight into how a-TTP may possibly function. The structure of a-TTP has been 
solved by means of X-ray diffraction and the protein has been shown to exist in two 
conformations: open and closed (Figure 3) [35]. The closed form (Figure 3A) was 
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determined with the ligand (a-tocopherol) in the hydrophobic binding site, whereas 
the open form (Figure 3B), the detergent Triton X-I00 replaced the ligand [35]. 
Comparison betweeu both conformations revealed changes in residues 202 - 212, that 
reside within an a-helix (a-lO) [36] , which forms the 'lid' to the hydrophobic binding 
site. The closed conformation, which is thought to be the "carrier protein state", 
shows that the ligand is buried deeply in the hydrophobic pocket covered by the lid. 
In the open state, or the "membrane docking form", the lid changes its position 
exposing the hydrophobic binding pocket [35]. Hence it is proposed that a-TTP in the 
open state attaches to a lipid bilayer, where it picks up an a-tocopherol substrate and 
transports it in the closed conformation [35]. 
The notion that a-tocopherol transfer by a-TTP involves direct protein-
membrane interaction is further supported by two recent studies using fluorescence 
resonance energy transfer (FRET) assays [37-38]. While the first study revealed an 
increase in the a-tocopherol transfer rate as a-TTP concentration increases [37] , the 
second study also showed an increase in the transfer rate when the concentration of 
acceptor phospholipid vesicles was increased [38]. If a-TTP adopted a diffusional 
mechanism, as opposed to a collisional mechanism, then increasing either the protein 
or acceptor vesicle concentration as mentioned in the above studies would not 
enhance the transfer rate of a-tocopherol [37-38]. Therefore, the results from these 
two studies further support the proposed mechanism of a-TTP, that it first binds to 
lipid membranes and picks up its ligand in the open conformation, followed by ligand 
transfer in the closed conformation. 
6 
A 
a-tocopherol 
.....;:="'-lIII~ 
binding pocket 
Lid (a-10) 
B 
a-tocopherol 
binding pocket 
Figure 3: (l-TTP sfnlcture. Shown here are the closed conformation with a-
tocopherol in the binding site (A) and the open conformation (B). Taken from Meier 
et al. [35). 
1.4 u-TTP-Mediated Transfer of a-Tocopherol 
To further understand the mechanism of u-TTP-mediated ligand transfer, 
where and how a-tocopherol is incorporated into VLDLs was investigated. Arita et 
al. demonstrated that the secretion of a-tocopherol is independent of the Golgi 
pathway where VLDL assembly occurs [34]. This was proven by over-expressing 
TTP in McARH7777 rat liver tumour cells in the presence of Brefeldin A, an inhibitor 
of VLDL secretion which disrupts the Golgi apparatus (GA) [34]. The secretion of 
triglyceride, a major lipid component of VLDL, was significantly inhibited, whereas 
a-tocopherol secretion was not affected [34]. This non-Golgi pathway of a-
tocopherol secretion was further illustrated by Traber et al. through the isolation of 
nascent VLDLs from the rough endoplasmic reticulum (RER) and GA membrane 
fractions from the livers of rats fed with equimolar ratios of deuterated RRR- and 
SRR-a-tocopherol [39]. The membrane fractions of the RER and GA were selected, 
as it is believed that VLDL assembly occurs through this route, such that the core 
lipids are assembled at the RER and then transported to the GA for further 
modification [39]. It was observed that the deuterated RRR:SRR ratio was 
7 
approximately 1 in both the RER and Golgi fractions as opposed to the serum which 
had a ratio greater than 3 [39]. If a-tocopherol enrichment of VLDLs occurs in the 
RER or GA, then the ratios of the deuterated RRR:SRR-a-tocopherol should be 
approximately the same as in serum [39]. 
The localization of a-TTP at late endosomes has been recently determined by 
means of fluorescence microscopy techniques [40-41]. a-TTP was seen in a punctate 
pattern resembling vesicular structures surrounding the nucleus in both cultured and 
fresh hepatocytes. To identify the intracellular organelle that a-TTP associates with, 
several antibody markers were used [40]. The results showed that a-TTP colocalized 
significantly with the lysosome-associated membrane protein-l (LAMP-I) marker, 
which is a resident protein of the late endosomesllysosomes (Figure 4) [40]. This 
evidence supports the work of Horiguchi et at., which demonstrated that chloroquine 
inhibits a-tocopherol secretion in cultured hepatocytes [41]. Chloroquine is known to 
accumulate within acidic compartments of late endosomes and lysosomes, 
neutralizing their luminal pH [41]. If the a-TTP-mediated-a-tocopherol secretion is 
affected when late endosomes and lysosomes are compromised, then an important 
role ofTTP within these organelles is implied. 
The colocalization of a-TTP with a-tocopherol was also investigated. Here, 
C9-NBD-a-tocopherol (7 -nitrobenz-2-oxa-l, -3-diazol-4-yl substituted tocopherol), a 
fluorescent analog of vitamin E was used [40]. NBD-tocopherol emits green 
fluorescence aiding in visualization and it mimics natural vitamin E due to its high 
affinity to a-TTP and reversible binding capability [40]. a-TTP was found to 
co localize with NBD-tocopherol - Figure 5 [40]. These experiments demonstrated 
that a-tocopherol enters liver cells and follows the endocytic pathway where it 
eventually ends up in late endosomes/lysosomes. This is in line with a previous study 
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by Rupar et al. that revealed lysosomes from rat livers were enriched with u-
tocopherol [42]. 
Figure 4: Colocalization of a-TTP with LAMP1 marker. When anti-a-TTP (green) 
(D) was overlaid with LAMP 1 marker (red) (E) both anti-a-TTP and LAMP 1 marker 
showed co localization (F). Takenfrom Qian et al. [40j. 
Figure 5: Co localization of a-TTP with NBD-tocopherol. NBD-tocopherol (green) 
colocalizes with anti-a-TTP (red) in the overlay window. Bar = 16 pM Taken from 
Qian et al. [40). 
A comparison between cells that express u-TTP and those that do not, showed 
that in u-TTP-expressing cells the NBD-tocopherol was found to be redistributed 
particularly around the cell periphery after 3 hours [40]. In cells that do not express 
u-TIP NBD-tocopherol remained in the perinuclear region, and only a small fraction 
was seen in the plasma membrane region [40] . 
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Another important piece of evidence provided by Horiguchi et al. using a 
dual-label fluorescence technique showed that a-TIP colocalized with 
lysobisphosphatidic acid (LBP A) [41]. LBP A is found in late endosomes, where it 
makes up about 15 % of late endosomal total phospholipids [43]. All these studies 
suggest that a-tocopherol delivered to liver cells eventually ends up in the late 
endosome via endocytosis [40]. a-TTP, which is found in the cytosol around this 
compartment, then picks up a-tocopherol and transfers it to the plasma membrane 
region to be packaged into nascent VLDLs [40l 
1.5 The Unique Properties of Lysobisphosphatidic acid (LBP A) 
LBPA, also known as bis(monoacylglycero)phosphate (BMP) was first 
isolated from the lungs of rabbits and makes up less than 1 % of the total 
phospholipids of animal tissues [44]. LBP A is now known as a unique lipid that 
constitutes about 15 % of the total phospholipid content in late endosomes as 
mentioned above [43]. It possesses a distinct structure in that the phosphodiester 
moiety is attached to the sn-l and sn-l' positions of glycerol as opposed to the sn-3 
position seen in most glycerol-phospholipids [45]. In addition, LBPA was thought to 
be esterified at the sn-3 and sn-3' position but a recent study indicates that the 2, 2'-
LBP A (Figure 6) is the major isoform in vivo [45]. Since LBP A is found 
predominantly in endosomal and lysosomal membranes, it is believed that its 
biosynthesis takes place here. Earlier investigation reveals that phosphatidylglycerol 
(PG) or lysophosphatidylglycerol (LPG) and cardiolipin (eL) are the main precursors 
of LBP A [46]. A recent study showed that PG was most likely the precursor of 
LBP A in mammalian cells; however the biosynthesis pathway of LBP A still remains 
to be elucidated [47]. 
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Figure 6: Structure of 2, 2 '- dioleoyl-LBPA. Taken from Matsuo et al. [45 j. 
The unique characteristic of LBPA stems from its pH-dependent fusogenic 
property. At a low pH of about 5.6, LBPA-containing liposomes are highly 
fusogenic, with this characteristic diminishing at higher pH values [44]. In a recent 
study, LBPA was found to promote multivesicular formation in liposomes at acidic 
pH as observed by fluorescence and cryo-electron microscopy (EM) - Figure 7 [45]. 
Liposomes with similar composition to late endosomes were prepared and were seen 
as unilamellar vesicles at neutral pH when LBPA was present (Figure 7C) [45]. 
When the luminal pH was dropped to about 5.5, multivesicular liposomes were seen 
only when LBPA was present (Figure 7D & 7E). Similar results were observed 
when the liposomes were observed by cryo-EM (Figure 7F & 7G). In addition, the 
invagination process of these liposomes was followed by the incorporation of the 
water-soluble dye 8-hydroxypyrene-l, 3, 6-trisulfonic acid (HPTS) at pH 5.5 [45]. 
Only in the presence of LBPA, the liposomes were capable of incorporating HPTS. 
Furthermore, when an antibody against LBP A was used, the invagination process was 
inhibited. This was not observed when an isotypic control antibody was used instead 
[45]. 
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Figure 7: Formation of multivesicular liposomes. Liposomes observed with a 
neutral luminal pH with LBPA present (C). Liposomes observed with an acidic 
luminal pH in the absence (D) and presence of LBPA (E) . C-E was obtained by 
fluorescence microscopy. Liposomes observed by cryo-EM in the absence (F) and 
presence (G) ofLBPA at acidicpH Takenfrom Matsuo et al. [45]. 
The multivesicular structures formed in the presence of LBP A at low pH in 
liposomes resemble those seen in late endosomes via electron microscopy [45]. Since 
the pH conditions of late endosomes are also around 5.5, the results from the 
aforementioned study supports the idea that LBP A may play a role in this 
multivesicular fonnation [45]. Also, in this study, the investigators noted that mainly 
the 2, 2'-LBPA isoform rather than 3, 3'-LBPA was capable to stimulate internal 
vesicle formation, a 100 % activity compared to 19 % respectively [45]. 
1.6 The Endocytic Pathway 
Endocytosis is the cellular uptake of substances from the extracellular 
environment via invagination and pinching-off of membrane-bound vesicles from the 
plasma membrane [48]. These vesicles, containing substances such as proteins and 
lipids, travel along a pathway that involves endosomes, eventually leading to the 
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lysosome for degradation [48]. Along the way, protein and lipid sorting takes place 
to ensure only those substances targeted for degradation arrive at the lysosome [48]. 
The process begins with the membrane-bound vesicles from the plasma membrane 
first fusing with early endosomes, the first sorting station [48]. Within the early 
endosomes, the pH is mildly acidic (6.2) and dissociation of some proteins and lipids 
from their receptors occurs [49]. The receptors are then recycled back to the plasma 
membrane via recycling endosomes [49]. The remaining substances targeted for the 
lysosome are packaged into intraluminal vesicles (ILVs). ILVs are small vesicles 
formed from the budding of the endosomal-limiting membrane into the endosomal 
lumen [48]. These early endosomes containing ILVs are believed to mature to form 
multivesicular bodies (MVBs) [50]. 
In recent literature, MVBs is used interchangeably with late endosomes [48, 
50-51]. Three forms of late endosomes have been recognized in HeLa cells, namely 
dense tubular, multilamellar and multivesicular [52]. Hence, MVB specifically refers 
to the multi vesicular late endosomes as opposed to the tubular and multilamellar 
forms. On the other hand, MVB has also been used interchangeably with endosomal 
carrier vesicles (ECVs) [49, 53]. These are recognized as intermediates between the 
early and late endosomes [49, 53]. In this thesis, the term MVB will be used for the 
late endosome. 
The late endosome is characterized by a decrease in the luminal pH to about 
5.5 [49] and an increase in the number of ILVs [54]. Fusion of MVBs to the 
lysosome results in the break-down of proteins and lipids that are no longer of 
functional value [55]. This was thought to be the only fate of MVBs [49]. However, 
current studies are showing that MVBs may possess other possible routes and 
therefore playa role in protein and lipid trafficking [55]. Hence, it appears that 
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MVBs act as the last sorting compartment before molecules are targeted for 
degradation in the lysosome [55]. An illustration of the endocytic pathway is seen in 
Figure 8. 
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Figure 8: Key stages of the endocytic pathway. Endocytosed materials such as 
protein and lipids enter firstly into the early endosomes. Receptors are recycled back 
to the plasma membrane via recycling endosomes. The early endosome then matures 
into the late endosome and .finally into the lysosome. Taken .ft"om Van Meel and 
Klumperman [48]. 
In recent work with the vesicular stomatitis virus (VSV) and anthrax toxin, 
MVBs were shown to undergo back-fusion with the limiting membrane of endosomes 
[54]. This is required for the release of viral nucleocapsids and toxins respectively 
into the cytoplasm [54]. In addition, MVBs can also undergo fusion with the plasma 
membrane [54]. This was observed for the major histocompatibility complex (MHC) 
class II molecules which are stored in MVBs [54]. In dendritic cells, MVBs act as 
storage compartments for MHC class II molecules [55]. Antigens taken up by the 
dendritic cell bind to the MHC complex, and are presented on the cell surface via the 
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fusion ofMVBs to the plasma membrane [55]. Similarly, MVBs can follow the same 
process releasing internal vesicles into the extracellular space [50]. These vesicles are 
known as exosomes and are observed in a variety of cells including dendritic cells, 
platelets, neurons and tumour cells [55]. Exosomes are defined as 30-100 nm vesicles 
originating from MVBs, and are released by fusion of the limiting membrane of 
MVBs to the plasma membrane [50]. In summary, the three recognized routes for 
MVBs so far are fusion with the lysosome, limiting membrane of late endosomes or 
the plasma membrane - Figure 9 [56]. 
~ MATURATION OF MVBs FATES OF MVBs 
1. 7 The Role of LBPA in the Endocytic Pathway 
Figure 9: Fates of MVBs. 
MVBs can either fuse to the 
limiting membrane of 
endosomes where molecules 
are sequestered to the 
limiting membrane or cytosol 
(1). Fusion of MVBs to the 
plasma membrane results in 
the release of exosomes (2). 
Finally, fusion of MVBs to 
the lysosome results in 
degradation (3) Taken from 
Van Niel et al. [56}. 
Lipid and protein composition, morphology, and function have been found to 
differ in endosomes along the endocytic pathway [57]. The early endosomes have a 
high amount of phosphatidylinositol-3-phosphate (PI(3)P), whereas the late 
endosomes have a significantly lower amount of this lipid. The reverse is true for 
LBPA, which is found predominantly in late but not early endosomes [58-59]. It has 
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been shown that MVBs targeted to different destinations have different lipid 
compositions in their membranes [59]. ILVs that develop into MVBs containing 
PI(3)P and ubiquitylated proteins are seen targeted to the lysosome as opposed to 
those enriched with LBP A [49). White et al. demonstrated that MVBs containing the 
epidermal growth factor receptor (EGFR) are distinct from LBPA-enriched MVBs 
[60). EGFR is known to associate with PI(3)P and both are required for MVB 
biogenesis. However, inhibition of PI-3-kinase activity did not prevent accumulation 
of LBPA-containing vesicles within the late endosome [60]. In addition, exosomes 
that are believed to be derived from MVBs show low LBP A content [61). Instead, 
latest studies on exosomes reveal that these vesicles are rich in ceramides [62). Hence 
it is evident that lipid composition and remodelling plays a role in intracellular 
trafficking. 
When antibodies against LBPA (known as 6C4) were used, the proper 
trafficking of the mannose-6-phosphate receptor (MPR) was disrupted [63). MPR 
delivers newly synthesized lysosomal enzymes from the trans-Golgi network (TGN) 
to late endosomes and vice versa for reutilization [63]. In baby hamster kidney 
(BHK) cells treated with 6C4, the receptor was found mainly in the late endosomes, 
where it colocalized with LBPA [63). Under normal conditions, the receptor was seen 
primarily in the TGN and did not show any significant colocalization with LBPA 
[63]. In another investigation, accumulation of cholesterol in late endosomes was 
observed when anti-LBPA was present [64]. Furthermore, again using antibodies 
against LBPA, it was demonstrated that the release of nucleocapsids into the cytosol 
by VSV was inhibited [54]. A similar result was seen with studies involving the 
anthrax toxin [54]. VSV and anthrax are known to infect cells through the endocytic 
pathway [54]. Both models reveal that entry into the cytoplasm requires the fusion of 
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internal vesicles to the limiting membrane of late endosomes known as back-fusion 
[54]. The resistance of LBPA to lipase and phospholipase activity could possibly 
explain its resistance to degradation in lysosomes [53]. This may account for the lack 
of its presence in ILVs targeted to lysosomes [53]. Also, it may provide an 
explanation for the evolution of viruses to take advantage of these vesicles to avoid 
the lysosomal pathway allowing it to infect its host [54]. 
The evidence clearly implies that LBP A plays a role in intracellular 
trafficking. Although MVBs are responsible for targeting to different destinations, it 
is plausible that LBP A-containing vesicles may be mainly involved in trafficking 
molecules targeted to the cytoplasm via the back-fusion mechanism. Since LBPA is 
capable of generating the formation of multivesicular structures in liposomes without 
the presence of proteins, this suggests that cellular trafficking within late endosomes 
can also be lipid-driven [45]. 
1.8 LBPA and Membrane Curvature 
The question on how LBP A is specifically involved in intracellular trafficking 
still remains to be answered. Biological membranes, which were once thought to 
mainly function as a barrier, are now proving to play more than one role. From the 
previous section, it is evident that membrane remodelling plays a role in intracellular 
trafficking. During membrane remodelling, budding and fusion of the membrane 
lipid bilayer are usually involved [65]. Budding and fusion of the membrane involves 
changes to the membrane curvature [65], hence there is interdependence between lipid 
domain formation and membrane curvature. This has been observed in both cell and 
model membranes [66]. So far five different mechanisms have been recognized that 
bring about membrane curvature: changes in lipid composition, influence of integral 
membrane proteins, cytoskeletal proteins and microtubule motor activity, scaffolding 
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by peripheral membrane proteins and active helix insertion into membranes [65]. 
Although specific proteins play an important role in the formation of membrane 
curvature, it is also highly dependent on the lipid composition [67]. Various parts of 
the bilayer structure and lipid physical properties are believed to contribute to the 
fusionlbudding process [67]. These include imperfect lipid packing, and changes of 
elastic free energy and membrane fluidity [67]. The focus here will be on membrane 
curvature brought about by changes in lipid composition. 
Membrane curvature can be positive, negative or zero. Positive curvature 
refers to the outer leaflet of a lipid bilayer that curves toward the aqueous phase due to 
the larger head-groups [65]. On the contrary negative curvature describes the outer 
leaflet curving away from the aqueous phase due to the smaller head-groups [65, 68-
69]. Zero curvature is used to describe the lipid bilayer when it approximates a 
straight line i.e. lamellar shape [65]. Membrane curvature is largely determined by 
the packing characteristics of lipids present within the membrane [68]. For example, 
phosphatidylcholine (PC) is a cylindrical shaped lipid where the cross-sectional area 
of the head-groups is identical to that of the fatty acyl chains [68]. Therefore a bilayer 
consisting solely ofPCs will produce a flat shape (zero curvature) - Figure lOA [68]. 
In contrast, phosphatidylethanolamine (PE) is a cone-shaped lipid [68]. As a result, 
this cone-shaped lipid exerts a negative curvature (Figure lOB) on the membrane due 
to the tighter packing of the smaller head-groups compared to the tail end [68]. On 
the contrary, an inverted cone-shaped lipid such as lysophosphatidic acid (LP A) will 
generate a positive curvature (Figure IOe) [68]. 
In support of the role of lipid composition in membrane fusion and fission, it 
has been observed that some lipids are required for certain fusion/fission reactions 
[70]. For example, PE appears to be required for the fusion of Golgi membranes, 
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while sphingolipid and cholesterol are necessary for the fusion mediated by Semliki 
Forest virus [70]. In the case of LBPA, we have seen from the work of Matsuo et al. 
that this lipid promotes multi vesicular morphology [45]. In addition, the fusion of 
intraluminal vesicles to late endosomes to release viral nucleocapsids during VSV 
infection is also dependent on the presence of LBP A [71]. It is noteworthy to mention 
here that although recent literature suggests that LBPA is a cone-shaped lipid by 
citing remarks made by Matsuo et at., there is no concrete evidence proving this. In 
fact, in Matsuo's 2004 paper, he only suggested that the 2, 2'-LBP A may be cone-
shaped. Even though the effect of LBPA on phospholipid bilayer polymorphism has 
not been fully established, it is clear that this lipid is able to regulate membrane 
curvature in the above-mentioned fusion processes. 
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Figure 10: A schematic diagram describing membrane curvature. A flat bilayer 
produced by PC (A); negative curvature due to cone-shaped lipids such as PE (B); 
positive curvature due to inverted cone-shaped lipids such as LPA (C). Taken from 
Atkinson et at. [J5}. 
The idea of membrane curvature being used as a means of recruiting proteins 
to membranes is one that cannot be dismissed. One protein that has been identified as 
associating with membranes in a curvature-dependent manner at the Golgi complex is 
the ArfGAPI protein (ADP-ribosylation factor GTPase activating protein 1) [69]. 
ArfGAPl is responsible for the dynamics of the COPI (coat protein complex 1) coat 
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at the Golgi complex [72]. Current investigations suggest that binding of Arf-GAPI 
is based on the shape of the lipid molecule and membrane curvature [72]. ArfGAP 1 
activity showed an increase when conical shaped lipids was introduced at a constant 
liposome radius. On the other hand, when the lipid composition was kept constant, 
ArfGAPl activity increased with membrane curvature [72]. Another example is the 
phosphoinositide 3-kinase (PI 3-kinase), which phosphorylates phosphatidylinositol 
(PI) [73]. When PI was presented in a convex (positive curvature) surface as opposed 
to a flat bilayer, the activity ofPI-3 kinase showed an increase [73]. In addition, PI-3 
kinase activity was also increased when vesicles with an average diameter of 50 nm 
were used as compared to vesicles with an average diameter greater than 300 nm [73]. 
1.9 Characterization of Protein-Lipid Interactions 
Understanding macromolecular interactions IS vital in elucidating many 
biological processes in living organisms. Here, the focus is to study protein-lipid or 
protein-membrane interactions. Surface plasmon resonance (SPR) is an established 
method for measuring such interactions [74]. It involves the immobilization of one 
reactant (the ligand) onto a biosensor chip surface and its interaction with a second 
component (the analyte) is monitored in solution [74]. The sensor chip in SPR is a 
glass slide coated with a thin layer of gold [75]. Polarized light is directed to the 
sensor chip and the change in refractive index caused by the binding of the analyte to 
the ligand is measured [74-75]. In protein-lipid interaction assays, the lipid is 
normally immobilized on the sensor chip followed by the injection of the protein 
across the chip [75]. The increase in protein mass due to lipid binding on the chip 
surface then causes an increase in the response [75]. SPR allows real time 
measurements without the need of protein and lipid labelling, requires small quantities 
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of samples (nearly nM concentrations of proteins) and also provides a rapid and direct 
mean of measuring the association and dissociation of binding processes [74-75]. 
Another technique that uses a similar approach is dual polarization 
interferometry (DPI). DPI is an optical sensing technique that involves two polarized 
light paths, hence the term 'dual polarization'. A sensor chip is also required, which 
consists of two optical waveguides stacked on top of each other, made of silicon 
dioxide doped with silicon nitride [76]. The top waveguide acts as a sensing 
waveguide, while the bottom is termed the reference waveguide. On the surface of 
the sensing waveguide are two etched sample wells, which allow the analyte to bind 
[77]. 
The theory behind DPI can be explained as follows. Polarized light is fed into 
the short end of the sensor chip [77]. When the polarized light enters the top and 
bottom waveguide, they are in phase. After passing through the sensor, the two 
beams from the two waveguides are allowed to diverge and form an interference 
pattem that is detected in the far-field [77]. The precise position of these bands is 
dependent upon the phase relationship of the light as it emerges from the two 
waveguides. Figure 11 illustrates the physical setup of the sensor chips and light 
paths used in DP!. 
Exposing the sensor chip to a sample changes the refractive index at the 
waveguide surface. This in tum alters the speed of light travelling through the 
sensing guide, whereas the speed of light passing through the reference guide remains 
the same since it has no contact with the analyte - Figure 12 [77]. The light 
travelling at constant velocity acts as an optical reference. The light emitted from 
both waveguides is now no longer in phase. Hence this results in a change in the 
interference pattem. This change in phase can be converted to refractive index and 
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thickness values using Fourier transfonnation [77]. The use of two components of the 
polarized light - transverse electric (TE) and transverse magnetic (TM) - allows 
measurements to be taken at right angles of each other [78]. Both components will 
respond differently, providing independent measurements. Since the refractive index 
value obtained is proportional to density, the layer density and mass of layer can 
therefore be calculated [78]. 
Sensing Wa'VElClIUICIEI 
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Figure 11: A schematic representation of the setup of DP 1. Light waves from a laser 
source pass through the sensor chip and produce an inteiference pattern in the far-
field. Taken from Teny et al. [79]. 
Figure 12: Illustration of the adsorbed analyte (lipid bilayer for example) on the chip 
surface. Upon binding of a second component (protein), the light path through the 
sensing waveguide is altered which results in a changed interference pattern. 
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Figure 13: Summary of the vesicle binding assay. The protein and lipid vesicles held 
within the sample reservoir are centrifuged to first produce the free protein fraction 
(filtrate). A further centrifugation step with the sample reservoir inverted yields the 
lipid-bound fraction (retentate). The individual fractions are analysed by SDS-P AGE 
followed by densitometry. 
DPI only allows protein interactions with planar lipid bilayers to be 
detennined; hence another method is required to study protein-lipid interactions that 
allow the comparison of lipid vesicles of different sizes. One such method is the 
vesicle binding assay (Figure 13). In addition to evaluating the role of lipid vesicle 
size, protein binding to the vesicles can also be assessed based on lipid composition, 
similarly to DPI. The vesicle binding assay involves the incubation of the protein of 
interest at a fixed concentration with varying amounts of the lipid. The sample 
mixture is then passed through a centrifugal filtration device with a molecular weight 
cut-off of 100 kDa to retain the lipid-bound proteins [37, 80]. This yields a filtrate 
containing the free protein fraction and a retentate holding the lipid-bound fraction. 
These fractions can then be further analysed with SDS-P AGE (Sodium Dodecyl 
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Sulphate Polyacrylamide Gel Electrophoresis) and densitometry to determine the 
protein binding affinity [79-80]. 
1.10 Project Outline 
Current studies reveal that a-TTP associates with late endosomes and possibly 
transfers a-tocopherol from here to the plasma membrane to be packaged into VLDLs 
[40]. However the detailed mechanism is not fully established. The late endosomes 
have been shown to be enriched with the lipid LBPA [44]. Moreover, LBPA appears 
to promote multivesicular formation as seen in late endosomes [45]. An initial study 
employing DPI analysis has demonstrated that a-TTP binding to artificial endosomal 
membranes containing LBPA shows some differences when compared to endosomal 
membranes without LBPA [81]. Using fluorescence resonance energy transfer 
(FRET) to study the transfer rate of the a-tocopherol ligand by a-TTP, it has been 
shown that small unilamellar vesicles (SUVs) containing only PC have higher transfer 
rates than LUVs [38]. 
Taking all these observations into account, it is plausible that LBPA may play 
a crucial role in the binding of a-TTP to late endosomes. Therefore, the aim of this 
project is to investigate the effect of LBP A on a-TIP binding to membranes -
specifically to determine whether a-rTP binds to membranes due to the presence of 
LBPA itself or due to the curvature effect generated by LBP A. To answer these 
questions, DPI will be used to determine the binding affinity of a-TTP to flat lipid 
bilayers in the presence .and absence of LBP A. Since low pH (pH 5.5) is important 
for LBPA to generate multivesicular structures [44-45], the binding affinity of a-TTP 
to LBPA-containing membranes will also be explored with DPI at this pH range in 
addition to physiological pH. 
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Since DPI only allows flat lipid bilayers to be investigated, it does not provide 
a proper means to study the curvature effect. Although one should be aware that the 
presence of LBPA in a flat membrane may cause its shape to be irregular due to 
curvature stress if LBP A truly regulates membrane curvature. This is based on the 
following assumption. A membrane bilayer that is naturally flat in structure will 
undergo curvature stress when it is forced to adopt a positive or negative curvature 
[82]. Similarly, a positive or negative curvature membrane will be stressed when it is 
forced to adopt a flat structure [82]. IfLBPA truly produces curvature in membranes, 
its presence will cause curvature stress in the flat bilayer on the sensor chip. 
However, the DPI method does not differentiate between the two effects that is the 
presence of LBP A itself and membrane curvature caused by LBP A. 
To further investigate the curvature effect on a-TTP binding to LBPA-
containing membranes, a vesicle binding assay will be employed. In the previous 
section, it is mentioned that the vesicle binding assay can be used to examine protein-
lipid interactions based on lipid composition and vesicle size. Here, both SUVs and 
large unilamellar vesicles (LUVs) will be used with and without LBPA present. In 
addition, the vesicle binding assays will also be compared at both physiological and 
low pH ranges as for the DPI experiments. Therefore, this method will allow us to 
determine whether a-TTP binding to membranes is dependent solely on the presence 
of LBP A or due to the curvature effect generated by LBP A. 
Finally, also using the vesicle binding assay, both forms of LBPA will be 
studied, that is the 3, I '-LBPA and 2, 2'-LBPA form. The 3, I '-LBPA is used instead 
of the 3, 3'-LBPA mainly because it is the only commercially available form of 
LBP A closest to the 3, 3' form. All studies will be conducted with the 3, l' -LBP A 
except where indicated since 2, 2'-LBP A is a costly lipid. The purpose of the final 
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investigation is to explore the effect of the two LBP A forms on u-TTP binding to 
LBPA-containing membranes. This is important since the 2, 2'-LBPA form has 
shown to possess a higher activity in multivesicular formation at pH 5.5 [45]. 
Therefore it is crucial to also investigate whether u-TTP binding changes when 2, 2'-
LBP A is present in vesicles as opposed to the 3, 3 '-LBP A form. 
Examining the effects of LBP A on u-TTP binding to membranes will provide 
further insight into the mechanism of u-TTP- mediated transfer of a-tocopherol. This 
is important since u-TTP is responsible for the plasma levels of vitamin Ein the body. 
Consequently this work will provide further understanding of vitamin E nutrition in 
health and disease. 
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2. MATERIALS AND METHODS 
2.1 Chemicals and Stock Solutions 
Sodium Chloride (NaCl) (Bioshop, Burlington, ON, Canada) 
Yeast extract (Bioshop, Burlington, ON, Canada) 
Tryptone (Bioshop, Burlington, ON, Canada) 
Ampicillin (Bioshop, Burlington, ON, Canada): 100 mg/mL in milliQ water, stored at 
-20°C 
Isopropyl-D-thiogalactoside (IPTG) (Bioshop, Burlington, ON, Canada): 1 M 10 
milliQ water, stored at -20°C 
Tris(hydroxymethyl)aminomethane (Tris) (Bioshop, Burlington, ON, Canada) 
Ethylenediaminetetraacetic acid (EDTA) (Bioshop, Burlington, ON, Canada) 
Dithiothreitol (DTT) (Sigma-Aldrich, St. Louis, MO, USA) 
Phenylmethanesulphonylfluoride (PM SF) (Sigma-Aldrich, St. Louis, MO, USA) 
Glycerol (Caledon Laboratory Chemicals, Georgetown, ON, Canada) 
Triton X-IOO (Sigma, St Louis, MO, USA) 
Magnesium Chloride (MgCb) (Bioshop, Burlington, ON, Canada) 
Lysozyme (Bioshop, Bioshop, Burlington, ON, Canada) 
Deoxyribonuclease I (Invitrogen, Carlsbad, CA, USA) 
RNase A, Pancreatic (Bioshop, Burlington, ON, Canada) 
Glutathione-Sepharose Beads (Sigma, St Louis, MO, USA) 
Thrombin protease (Amersham Biosciences now part of GE Healthcare, Piscataway, 
NJ, USA) 
Glutathione (Bioshop, Burlington, ON, Canada) 
Precision Plus Unstained Protein Marker (Biorad, Hercules, CA, USA) 
Potassium Phosphate Dibasic (Bioshop, Burlington, ON, Canada) 
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Bradford Reagent (Sigma-Aldrich, St Louis, MO, USA) 
Glycine (Sigma, St Louis, MO, USA) 
Acetic Acid (Caledon Laboratory Chemicals, Georgetown, ON, Canada) 
Sodium Dodecyl Sulfate (SDS) (Sigma, St Louis, MO, USA) 
Anhydrous Ethyl Alcohol (Commercials Alcohols mc., Brampton, ON, Canada) 
Methanol (Fisher Scientific, Fair Lawn, NJ, USA) 
Isopropanol (IPA) (Caledon Laboratory Chemicals, Georgetown, ON, Canada) 
Sucrose (Bioshop, Burlington, ON, Canada) 
Potassium Chloride (KCI) (Bioshop, Burlington, ON, Canada) 
Proto Blue Safe (Colloidal Coomasie Stain) (National Diagnostics, Atlanta, GA, USA) 
2-(N-Morpholino)ethanesulphonic acid (MES) (Bioshop, Burlington, ON, Canada) 
S, S Bisoleoyl-LBPA (Echelon Biosciences, Salt Lake City, UT, USA) 
1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) (Avanti Polar Lipids mc., 
Alabaster, AL, USA) 
1, 2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) (Avanti Polar Lipids mc., 
Alabaster, AL, USA) 
1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (Avanti Polar Lipids mc., 
Alabaster, AL, USA) 
Sphingomyelin (Brain, Porcine) (Avanti Polar Lipids Inc., Alabaster, AL, USA) 
L-a-phosphatidylinositol (Liver, Bovine) (Avanti Polar Lipids Inc., Alabaster, AL, 
USA) 
Bis(monooleoylglycero)phosphate (S, R) (Avanti Polar Lipids Inc., Alabaster, AL, 
USA) 
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2.2 Buffers and Solutions 
2.2.1 Bacterial cell culture and protein expression 
Luria Bertani (LB) Broth: 5 giL NaCl, 5 giL yeast extract, 10 giL tryptone 
LB-Amp medium: LB medium supplemented with 50 J.lglmL ampicillin 
2.2.2 Protein purification 
Buffer A: 150 ruM Tris pH 8, 150 mM NaCl, 1 mM EOTA pH 7.5, 10 % 
glycerol, 0.1 ruM OTT, O.lmM PMSF 
Buffer B: Buffer A supplemented with 0.5 % Triton X-IOO & 10 mM MgCh 
Buffer C: 50 mM Tris pH 8, 150 mM NaCI, 10 mM MgCh, 0.1 ruM OTT 
Phosphate Buffered Saline (PBS): 25 mM potassium phosphate dibasic, 137 
mMNaClpH8 
Glutathione Elution Buffer: IX PBS supplemented with 4 mglmL glutathione 
Cleansing Buffer 1: 0.1 M borate buffer (boric acid), 0.5 M NaCl pH 8.5 
Cleansing Buffer 2: 0.1 M acetate buffer (sodium acetate), 0.5 M NaCl pH 4.5 
Storage Buffer: 2 M NaCl 
2.2.3 SDS-PAGE electrophoresis 
SOS-PAGE Stacking Buffer: 0.5 M Tris pH 6.8 
SOS-PAGE Separating Buffer: 1.5 M Tris pH 8.8 
SOS-PAGE Running Buffer: 125 ruM Tris, 960 mM glycine, 0.5 % SOS pH 
8.3 
SOS-PAGE Loading Dye: 50 mM Tris, 16 % glycerol, 16 % SOS (10 %), 0.02 
% OTT, 0.08 % bromophenol blue (1 %) 
Fixing Solution: 50 % methanol, 10 % acetic acid 
Gel Drying Solution 1: 40 % methanol, 10 % glycerol, 7.5 % acetic acid 
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2.2.4 Dual polarization interferometry 
DPI Running Buffer: 10 mM potassium phosphate dibasic, 137 mM NaCI pH 
7.4 
Calibration Solutions: 80 % ethanol, milliQ water 
Wash Solutions: 2 % SDS, 50 % isopropanol (IPA) 
2.2.5 Vesicle binding assay 
SET Buffer: 250 mM Sucrose, 1 mM EDT A, 50 mM Tris, 100 mM KCI pH 
7.5 
SET Buffer + Triton X-IOO: SET buffer supplemented with 100 11M TritonX-
100 
MES Buffer: 250 mM Sucrose, 1 mM EDT A, 50 mM MES, 100 mM KCI pH 
5.5 
MES Buffer + Triton X-IOO: MES buffer supplemented with 100 11M Triton 
X-100 
2.3 Equipment 
Spectronic® GenesysTM 2 spectrophotometer (Spectronic Instruments, Leeds, UK) 
Sorvall® MC 12 microcentrifuge (Mandel Scientific Co. Ltd., Guelph, Ontario) 
Sorvall® RC 5C Plus with SLA-3000 and SS-34 rotors (Mandel Scientific Co. Ltd., 
Guelph, Ontario) 
Sorvall® RMC14 (Mandel Scientific Co. Ltd., Guelph, Ontario) 
Coming pH meter 445 (Coming, Lowell, Massachusetts) 
TC-7 test tube roller (New Brunswick Scientific Co. Inc., Edison, New Jersey) 
Shaker Incubator (Gallenkamp, Loughborough, UK) 
Mini-PROTEAN III Cell (Bio-Rad Laboratories, Mississauga, ON, Canada) 
10IU Peristaltic Pump (Watson Marlow, Concord, ON, Canada) 
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Farfield Analight® Bi0200 (Farfield Scientific Ltd., Crewe, UK) 
Microcon (Millipore Corporation, Bedford, MA, USA) 
Mini-Extruder (Avanti Polar Lipids Inc., Alabaster, AL, USA) 
Liposofast-Basic (A vestin, Ottawa, ON, Canada) 
Polycarbonate filters - 100,200 and 400 nm (Avestin, Ottawa, ON, Canada) 
W-375 Sonicator cell disruptor (Misonix, Inc., Farmindale, NY, USA formerly known 
as Heat Systems-Ultrasonics, Inc.) 
Cellulose Dialysis Tubing (Fisherbrand, Nepean, ON, Canada) 
Unmodified sensor chip - FB85 (Farfield Scientific Ltd., Crewe, UK) 
Ready gels - 15 % Tris-HCI (Biorad, Hercules, CA, USA) 
Optima XL-lOOK Ultracentrifuge (Beckman Coulter, Missisauga, ON, Canada) 
Gel Drying Film (promega Corporation, Madison, WI, USA) 
2.4 Software 
Scion Image for Windows (Scion Corporation, Frederick, MD, USA) 
GraphPad Prism for Windows, Version 5.0 (GraphPad Software Inc., La Jolla, CA, 
USA) 
Farfield Analight® Bi0200, Version 2.1.21 (Farfield Scientific Ltd., Crewe, UK) 
2.5 Bacterial Strain 
BL21 (DE3) Escherichia coli (E. coli) was used for protein expression (Stratagene, La 
Jolla, CA, USA) 
2.6 Plasmid 
pGEX 4T-3 (GE Healthcare) was used for the expression of wild-type a-TTP. The a-
TIP gene was previously cloned into the pGEX 4T-3 vector at the SaIl and NotI sites 
[83]. 
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2.7 Methods 
2.7.1 Protein expression of wild-type a-TTP 
Four test tubes containing 10 mL each of autoclaved LB Broth were 
supplemented with 100 flg/mL ampicillin. Each test tube was inoculated from a 
frozen culture of BL21 (DE3) E. coli cells containing pGEX 4T -3/ u-TTP construct. 
The cultures were then grown overnight at 37°C in a test tube roller. On the next day, 
six 1 L baffled flasks containing 500 mL of autoclaved LB broth were inoculated with 
5 mL of the overnight culture to produce a 1: 100 dilution factor. The cultures were 
allowed to grow at 37°C on a shaker at 180 rpm until an OD600 of 0.4 - 0.6 was 
achieved. The flasks were then left to cool at room temperature. Following that, TTP 
expression was induced by the addition of 200 flL of 1 M lPTG (final concentration 
of 0.4 mM). The flasks were left overnight at room temperature on a shaker. The 
cells were harvested by centrifugation at 9000 rpm for 10 minutes. The supernatant 
were decanted and the remaining cell pellets were stored at -80°e. 
2.7.2 Purification of GST-Fusion a-TTP 
A frozen cell pellet was thawed and frozen at -80°C three times for cell lysis 
purposes. Then the cells were suspended in 10 mL of Buffer A with 400 flL of 100 
mg/mL lysozyme to yield a final concentration of 4 mg/mL. The solution was left to 
incubate for 30 minutes on ice. Following that the solution was treated with the 
following: 20 flL of 5 M MgCh (final concentration of 10 mM), 10 flL 100 % Triton 
X-100 (final concentration 0.1 %), 1000 units DNAse, 50 flL of 10 mg/mL RNAse 
(final concentration of 50 flg/mL) and left to incubate for a further 30 minutes on ice. 
Then, the lysate was passed through an 18G 1 liz needle attached to a 10 ml syringe for 
5 to 6 times followed by sonication three times for 30 seconds at approximately 10 -
32 
15 watts. The cell debris was removed by centrifugation at 17500 rpm for 25 minutes 
at 4°C. 
A column containing 1 mL of glutathione-sepharose beads was prepared and 
washed with 10 mL of 1 X PBS followed by lO mL of Buffer B. All solutions were 
passed through the column by means of a peristaltic pump with a flow rate of 25 rpm. 
Then the supernatant was added to the pre-washed column. Subsequently the column 
was washed first with a 10 mL of Buffer B and secondly Buffer C. 50 ilL (50 units) 
of thrombin were diluted in 950 ilL of IX PBS and added to the column and allowed 
to incubate for 2 hours at room temperature on a bench top roller. The protein was 
eluted from the column with 5 mL Buffer C giving a total of 5 1 mL fractions. Next, 
the column was washed with a further 10 mL of Buffer C. The GST tags were then 
eluted from the column with 4 mL of Glutathione Elution Buffer. The column was 
regenerated with Cleansing Buffer land milliQ water followed by Cleansing Buffer 2 
and milliQ water. Finally the column was stored in 2 mL of2 M NaCI at 4°C. 
2.7.3 Protein quantitation: Bradford assay 
The protein concentration from a given purification was quantified using the 
Bradford assay. A standard curve of absorbance measured at 595 nm versus the 
concentration of bovine serum albumin (BSA) ranging between 0 - I mg/mL was 
prepared. Each standard was prepared by adding 50 ilL of BSA solution to I mL of 
Bradford reagent. After incubation for 5 minutes at room temperature, the absorbance 
was measured. The concentration of unknown protein samples were then determined 
from the standard curve and the conditions used were similar to those applied to the 
BSA samples. Protein samples exceeding 1 mg/mL were diluted with PBS buffer and 
the final concentration was corrected for the dilution factor used. 
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2.7.4 Protein characterization: SDS-PAGE analysis 
SDS-PAGE analysis was used to determine the purity of the purified protein. 
SDS-PAGE loading buffer was added to each sample to yield a final amount of 5 Ilg 
of protein. A 15 % acrylamide separating gel with a 5.5 % stacking gel was prepared 
in a Mini-Protean 3 casting system according to manual specifications. The protein 
samples were treated by heating at 95°C for 10 minutes to fully denature the proteins. 
Samples were then loaded onto the gel along with a protein molecular weight marker 
and ran for two hours at 100 - 110 V. After that the gel was soaked in fixing solution 
for an hour with gentle rocking. Then the gel was washed with distilled water 
followed by overnight staining in Coomasie Brilliant Blue staining solution again 
with gentle rocking. Next, the gel was soaked in de staining solution to remove 
background dye. Finally, the gel was soaked in gel preserving solution for 30 minutes 
and clamped between two acetate sheets and allowed to dry to create a permanent 
record. 
2.7.5 Protein dialysis 
All protein samples that were run on the Analight Bi0200 were dialysed with 
DPI running buffer to avoid bulk phase changes. Approximately 1 mL of protein 
sample was loaded into a regenerated cellulose dialysis tube with a molecular weight 
cut-off of 3.5 kDa. The dialysis tubing was regenerated in milliQ water for 20 
minutes followed by DPI running buffer for a further 20 minutes. Protein samples 
were dialyzed for approximately one hour in DPI running buffer at 4°C to minimize 
protein loss. 
2.7.6 Large unilamellar vesicle (LUV) preparation for DPI 
LUVs were prepared with a final concentration of 2.54 mM. When mixed 
lipid composition was used, the preparation was based on mole fractions of the final 
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concentration. Table 1 summarizes the lipid composition and concentration of the 
three lipid membrane system investigated in this project. 
Lipid stocks were purchased dissolved in chloroform. The desired volumes of 
lipids were transferred to an 8 mL glass vial and dried under nitrogen gas to remove 
the solvent. The glass vials were then transferred to a high vacuum apparatus for an 
hour to completely remove residual chloroform. The remaining lipid stocks were 
stored in 8 mL glass vials at -20°C flushed with nitrogen gas. The dried lipids were 
rehydrated with DPI running buffer for one hour at room temperature. After 
hydration, the lipids were extruded using the Mini-Extruder or Liposofast-Basic 
through a 100 nm polycarbonate filter for fifteen times to produce 100 nm LUV s. 
Rehydrated LUVs were stored at 4°C until further use. LUVs stored at 4°C were used 
for up to three to five days. 
Membrane Concentration 
System 
Lipid % Composition (mM) 
90:10 DOPC 90 2.28 
DOPC:DOPS DOPS 10 0.25 
DOPC 65 1.65 
DOPS 5 0.13 
Endosomallipids 
DOPE 20 0.51 
without LBP A 
SM 5 0.13 
PI 5 0.13 
DOPC 50 1.27 
DOPS 5 0.13 
Endosomallipids DOPE 20 0.51 
withLBPA SM 5 0.13 
PI 5 0.13 
LBPA 15 0.38 
Table 1: Summary of lipid composition and concentration of 90:10 DOPC: DOPS, 
endosomallipids with and without LBPAfor DPI. 
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2.7.7 LUV preparation for vesicle binding assay 
For the vesicle binding assay, LUVs were prepared as in Section 2.7.6 with a 
final concentration of 2 mM. The lipid composition and concentration used here are 
shown in Table 2. In this case, the dried lipids were rehydrated with the buffers used 
in the vesicle binding assay - SET and MES buffer respectively. In addition, 200 nm 
and 400 nm polycarbonate filters were used to prepare 200 and 400 nm LUVs 
respectively. 
Membrane Concentration 
System 
Lipid % Composition 
(mM) 
90:10 DOPC 90 1.80 
DOPC:DOPS DOPS 10 0.20 
DOPC 65 1.30 
DOPS 5 0.10 
Endosomallipids 
DOPE 20 0.40 
without LBP A 
SM 5 0.10 
PI 5 0.10 
DOPC 50 1.00 
DOPS 5 0.10 
Endosomallipids DOPE 20 0.40 
with LBPA SM 5 0.10 
PI 5 0.10 
LBPA 15 0.30 
Table 2: Summary of lipId composition and concentration of 90: I 0 DOpe: DOP8, 
endosomallipids with and without LBP A for vesicle binding assay. 
2.7.8 Small unilamellar vesicle (SUV) preparation for vesicle binding assay 
The initial steps in SUV preparation for vesicle binding assay purposes were 
similar to LUV preparation with a final concentration of 2 mM. The lipid 
composition and concentration used are similar to those in Table 2. SUVs were 
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prepared by rehydrating the dried lipids in SET or MES buffer for one hour at room 
temperature. The rehydrated lipids were then sonicated with a probe sonicator for 45 
minutes. Titanium particles from the probe sonicator were removed by ultra-
centrifugation at 30 000 rpm (IOO 000 g) for one hour and 30 minutes. The SUV s 
were similarly stored at 4°C until further use. The shelf-life for SUVs stored at 4°C 
was typically up to 3 - 4 days. 
2.7.9 Dual polarization interferometry 
The Analight Bi0200 was set up by allowing DPI running buffer to pump 
through for an hour prior to running an experiment. Following that an unmodified 
sensor chip was cleaned with isopropanol and loaded into the machine according to 
the manufacturer's protocol. The sensor chip was then calibrated with 80 % ethanol 
and milliQ water. Once calibration was completed, a 400 ilL sample containing the 
desired lOO nm LUVs was injected onto the sensor chip at a flow rate of25 Ill/min for 
8 minutes. The phospholipid layer was allowed to adsorb unto the chip until a stable 
layer was formed. Then a 400 ilL sample of u-TTP solution of the desired 
concentration was injected with similar conditions as the phospholipid layer. The 
volume for both protein and lipid samples are as recommended by the manufacturer 
and are sufficient to produce a signal at a flow rate of 25 Ill/min. The protein layer 
was monitored for a further 10 minutes after the 8 minute injection to ensure 
sufficient data collection. The sensor chip was then regenerated with 2 % SDS 
solution followed by 50 % IP A solution. Upon regeneration, subsequent lipid and 
protein injections were performed. Generally, to determine the binding affinity of 
TIP to an adsorbed phospholipid layer, an increasing amount of u-TIP concentration 
was used, typically between 62.5 - 2000 nM. In the case of measuring the thickness 
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of a phospholipid layer, only the phospholipid solution was injected unto the chip. 
The lifetime of a single sensor chip is averagely between 50 - 70 sample injections. 
2.7.10 DPI data analysis 
The signal elicited by the association of a-TTP to lipid membranes on the 
Analight Bi0200 is determined by the maximum mass of a-TTP deposited on to the 
lipid layer. To obtain a Kd value, data were collected for a series of injections at eight 
different concentration of protein. All protein and lipid samples are injected twice. 
However, due to the two-channel geometry of the sensor chip in the DPI instrument, 
two measurements are obtained for a single injection. Since two injections were 
performed for each protein concentration, the four resulting measurements were used 
for data analysis. All graphs were plotted using GraphPad Prism. The mass data over 
a 480 s time frame for each a-TTP concentration were fit to a one phase exponential 
association model. The equation is as follows: 
y = Y max (l - e - let) (1) 
With reference to (1), Y = mass of a-TTP bound, Ymax = maximum mass of a-TTP 
bound, t = time, k = rate constant. The maximum mass of a-TTP bound to the lipid 
bilayer for each (l-TTP concentration was then used to plot a saturation binding curve 
with the following equation to obtain the Kd value: 
Y = Bmax * X / (Kd + X) (2) 
With reference to (2), Y = maXImum mass of protein deposited at a gIVen 
concentration, Bmax = maximum number of binding sites, X = a-TTP concentration 
and Kd = dissociation constant. The binding curves were treated with relative 
weighting. According to Prism, relative weighting is used when the average distance 
of the data points from the curve increases as Y increases. 
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2.7.11 Vesicle binding assay 
YM-lOO microcons were pre-wet with 100 JlL SET or MES buffer and spun at 
7500 rpm for 30 minutes in a microcentrifuge. At the same time, 31.5 Jlg of TTP was 
incubated with 0 - 1.5 mM vesicles (SUVs or LUVs) in a total volume of 200 JlL for 
30 minutes at room temperature with constant and gentle mixing. The TTP-vesicle 
complex was then added to the hydrated microcons and spun for 20 minutes at 9500 
rpm. After that, an additional 100 JlL of SET or MES buffer was added unto the 
microcon and the centrifugation was repeated. The resultant flow-through from the 
two spins is known as the filtrate or free protein fraction. The rnicrocon was then 
inverted and transferred to a new collection tube. 100 JlL of SET or MES buffer 
supplemented with 150 JlM Triton X-I00 was added unto the rnicrocon and spun at 
3500 rpm for 3 minutes. This process was repeated an additional two times. The 
flow-through from the three spins represents the retentate or membrane-bound 
fraction. The fractions were then characterized by SDS-PAGE followed by 
densitometry. 
2.7.11 SDS-PAGE analysis of vesicle binding assay fractions 
The procedure used here are similar to those described in Section 2.7.4 but in 
this case commercial ready-made gels were used. Also, instead of staining the gels 
with Coomasie Brilliant Blue solution, Colloidal Coomassie stain was used. The gels 
were then de stained with distilled water. 
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2.7.12 Densitometry analysis 
The gels containing the vesicle binding assay fractions were scanned and 
saved as a TIFF (Tagged Image File Format) file. Using the software Scion Image for 
Windows, band intensities were obtained. The band intensities were then used to plot 
a binding affinity curve - see Results & Discussion for further details. All band 
intensities were treated by removal of the background gel intensity. 
2.7.13 Investigation of a-TTP stability at low pH conditions 
315 Ilg of a-TIP was mixed in 2 mL ofMES buffer of pH values of6.5, 6.0 and 
5.5. The mixture was mixed thoroughly and centrifuged for 5 minutes at 12000 rpm. 
A 50 ilL sample was removed to test for protein concentration using the Bradford 
assay. The original mixture was resuspended and left to stand at room temperature. 
Protein concentration measurements were taken at one hour intervals starting from 
time = 0 hour over a three hour period. 
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3. RESULTS AND DISCUSSION 
3.1 Characterization ofTTP by SDS-PAGE 
The purification of a-TTP was carried out by means of affinity 
chromatography using agarose beads containing immobilized glutathione. The 
glutathione-agarose beads bind GST-TTP and the GST-tag is then removed by 
cleavage using thrombin, a serine protease. Figure 14 shows a typical SDS-PAGE 
gel demonstrating the purification procedure. 
50kDa 
37kDa 
25kDa 
1 2 3 4 5 6 7 8 9 
58kDa 
.~----- 32 kDa 
Figure J4: SDS-PAGE gel of a-TTP purification. Molecular weight marker (1), 
empty (2,5 & 10), cell lysate (3), supernatant (4),jlow through (6), pure a-TTP from 
fraction one (7), pure a-TTP from fraction two & GST tag (9). 
Lane one contains the molecular weight marker. Lanes three and four were 
loaded with bacterial cell lysate and supernatant respectively. The band at 58 kDa 
corresponds to GST-TTP while the band at 32 kDa represents a-TTP. Lane six holds 
the flow-through. No visible band observed here indicates the binding of GST-TTP to 
the agarose beads. The 32 kDa band in lanes seven and eight corresponds to pure a-
TTP after treatment with thrombin. However, it should be noted that there are some 
traces of impurities in lanes seven and eight but they do not correspond to GST -TTP, 
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since these impurities are of higher molecular weight. Finally the band at 26 kDa in 
lane nine represents the GST-tag after elution with glutathione. A typical yield can 
vary between 3 to 5 mg/mL of pure a-TTP from 3 g of wet cell pellet. 
3.2 Investigation of u-TTP-Lipid Membrane Interactions Using DPI at 
Physiological pH Conditions 
3.2.1 Deposition of phospholipid vesicles on to silicon oxynitride sensor chips 
In order to investigate the interactions of a-TTP with lipid membranes on the 
Analight Bi0200, LUVs were first deposited on to the surface of unmodified silicon 
oxynitride sensor chips. A convenient method for creating supported lipid bilayers 
(SLBs) is through vesicle fusion, a method developed by McConnell and co-workers 
as cited by Schonherr et aZ. [84]. The solution containing the LUVs of interest is 
injected into the Analight Bi0200 and when the vesicles come into contact with the 
silicon sensor chip, they undergo vesicle rupture and adsorption to the surface. Much 
investigation has been conducted to understand the detailed mechanism of vesicle 
adsorption on solid supports [84]. The current model for the formation of SLBs can 
be described as follows and will serve as a general model for the deposition of LUVs 
unto the sensor chip in the Analight Bi0200. Firstly, the vesicle approaches and 
adsorbs unto the solid support - Figure 15 (1). The adsorbed vesicle then deforms or 
flattens. Next, vesicle fusion may occur to form larger vesicles - Figure 15 (2) -
followed by vesicle rupture to form SLBs - Figure 15 (3). Finally, merging occurs to 
form a continuous bilayer over the solid support - Figure 15 (4) [84]. 
An important prerequisite in examining protein-lipid interactions m the 
Analight Bi0200 is the formation of a stable phospholipid bilayer. This stability is 
characterized by the thickness of the flat phospholipid layer formed and that it 
remains constant throughout the entire period of protein deposition. A stable bilayer 
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is considered to have been produced when a measurement of bilayer thickness has 
reached a constant value. Therefore, before the binding of u-TTP to lipid membranes 
was assessed, the deposition of phospholipid vesicles onto sensor chips was first 
examined by means of bilayer thickness measurements. In this project, three different 
lipid mixtures were used in the investigation of u-TIP binding to lipid membranes, 
including 90:10 DOPC:DOPS, endosomallipids with and without LBPA. The bilayer 
thickness measurements obtained for these lipid systems are shown in Table 3. The 
measured thickness of a 90:10 DOPC:DOPS (which from here onwards will be 
referred to as just DOPC:DOPS) lipid bilayer ranged between 4 to 4.5 llill . These 
values are an indication that the DOPC:DOPS vesicles form a single planar bilayer, 
since the thickness of a single planar bilayer has been found to be approximately 5 nm 
[85]. 
... 
Figure 15: Formation of supported lipid bilayers (SLBs). Lipid vesicle adsorbs and 
flattens on the solid support (1). Vesicle fusion may occur to form larger vesicles (2). 
Vesicle nlpture then takes place to form the SLB (3) and finally a continuous bilayer 
is produced through merging (4). Takenfrom Schonherr et al. [84]. 
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LUV Composition Bilayer Thickness ~easurements(nm) 
90 % DOPC:I0 % DOPS 4 -4.S 
Endosomallipids without 
zS.S 
LBPA 
Endosomallipids with 
z 6.S 
LBPA 
Table 3: Lipid bilayer thickness measurements/rom DPI analysis. 
The ability of a lipid vesicle to adsorb to a surface and transform into a planar 
bilayer can be influenced by many factors [84], including the presence of curvature-
forming lipids or non-bilayer lipids [86]. Hamai and co-workers demonstrates this 
point clearly. Using fluorescence microscopy, the effect of average phospholipid 
curvature on SLB formation by vesicle fusion was investigated [86]. The 
investigation showed that the ability of vesicles to rupture and form SLBs is affected 
by the geometry of the lipids present within the vesicle. As the proportion of 
curvature-forming lipids such as PE increases within the vesicle, the ability to form 
planar bilayers diminishes [86]. When the proportion of non-bilayer lipids is 
sufficiently high, vesicles will rather remain intact than form a planar bilayer. On the 
other hand, when non-bilayer lipids are present at low quantities or not at all, the 
vesicles are more easily deformed and can rupture to form an adsorbed single bilayer. 
The inclusion of non-bilayer lipids into a monolayer will result in the 
monolayer adopting a certain curvature. The consequence of forcing two mono layers 
of the same curvature into a flat bilayer leads to a build up of curvature stress (or 
elastic stress), since the monolayers' natural tendency is to curve rather than remain 
flat [87-88]. As a result of this curvature stress, the bilayer can undergo physical 
changes such as an increase in the overall bilayer thickness [88-89]. The 
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aforementioned description may then account for the increased lipid bilayer thickness 
observed for both the endosomal lipids with and without LBP A present when 
compared to DOPC:DOPS lipids. This is because endosomal lipids without LBPA 
contain DOPE which induces negative curvature. On the other hand, endosomal 
lipids with LBP A present contain PE and LBP A, which both are non-bilayer lipids. 
In addition, a recent study showed that LBPA-containing vesicles spontaneously form 
highly curved vesicles [90]. Therefore, the increase in the proportion of non-bilayer 
lipids within the LBPA-containing lipids can rationalize the further increase in 
thickness layer as seen in Table 3. 
Adsorbed PC bilayer 
1 larger thickness 
Adsorbed bilayer containing LBP A 
Figure 16: An illustration of how non-bilayer lipids may affect the SLB thickness. 
The presence of curvature-inducing lipids such as LBPA causes the planar lipid 
bilayer to be stressed. The stressed bilayer is represented as an irregular swiace (but 
may not necessarily depict the true condition) which results in an increased bilayer 
thickness on average. Partially uncollapsed vesicles on the sensor chip surface may 
also contribute to an increased bilayer thickness. 
Also, partially uncollapsed vesicles on the sensor chip surface may explain the 
increased bilayer thickness. These partially uncollapsed vesicles possess a greater 
layer thickness and therefore contribute to the overall increased bilayer thickness, 
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since DPI measures the average thickness of the bilayer on the sensor chip. An 
illustration of this rationalization is provided in Figure 16. 
3.2.2 Interaction of a-TTP with 90:10 DOPC:DOPS lipid layer 
In order to show that u-TTP binds to lipid membranes, it was first necessary to 
investigate u-TTP's interaction with a simple lipid system. The DOPC:DOPS lipid 
system was chosen due to its ability to form a stable bilayer on the DPI rapidly and 
reproducibly. Figure 17 shows the saturation binding curve of u-TTP with 
DOPC:DOPS with a Kd value of 877 ± 102 urn (Bmax = 1.98 ± 0.134 ng/mm2). This 
result indicates that u-TTP possesses the ability to bind to lipid membranes. 
2.0 
Kd= 877 ± 102 nM 
1.5 Bmax = 1.98 ± 0.134 ng/mm2 
1.0 
0.5 
O.O+---~---'T'""--"""'T---""""-
o 500 1000 1500 2000 
(1.-TIP Concentration (nM) 
Figure 17: Plot of maximum specific mass of a-TTP bound to DOPCDOPS lipid 
layer. DOPCDOPS lipid is made up of 90 mol% DOpe and 10 mol% DOPS with a 
final lipid concentration of 2.54 mM Data are representative of four measurements 
from two independent sample il?iections. 
3.2.3 Interaction of a-TTP with endosomallipids with and without LBP A 
Since the objective of this project is to investigate the effect of LBPA on u-
TIP binding to lipid membranes, it was necessary to investigate u-TTP binding to 
lipid membranes without the presence of LBP A as a comparison. Here the lipid 
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membrane composition of interest is the endosomal lipid mixture as described by 
Kobayashi et af. [44]. The affinity of a-TTP for endosomal lipids without LBPA 
present were close to that of the DOPC:DOPS lipids with a Kd value of 902 ± 191 nM 
(Bmax = 1.42 ± 0.176 ng/mm2). Figure 18 shows the binding affinity curve for a-TTP 
to endosomallipids without LBP A. 
1.5 
Kd= 902 ± 191nM 
Bmax = 1.42 ± 0.176 ng/mm2 
1.0 
0.5 
O.O+---"""T"---r----""T""----r-
o 500 1000 1500 2000 
(1.-TIP Concentration (nM) 
Figure 18: Plot of maximum specific mass ofa-TTP bound to an artificial endosomal 
lipid mixture without LBP A. Endosomal lipids without LBP A are made up of 65 
mol% DOpe, 20 mol% DOPE and 5 mol% DOPS, SM and PI with a final lipid 
concentration of 2. 54 mM Data are representative of four measurements from two 
independent sample injections. 
However, when LBPA was present, the affinity of a-TTP for lipid membranes 
increased by two-fold as reflected by the lower Kd value of 328 ± 64.6 nM (Bmax = 
1.24 ± 0.096 ng/mm2). Figure 19 illustrates the binding affinity curve for a-TIP to 
endosomallipids with LBPA. 
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2.0 
Kd= 328 ± 64.6 nM 
Bmax = 1.24 ± 0.096 ng/mm2 
O.O-f---"""T""--~-----'r---r--­
o 500 1000 1500 2000 
a.-TIP Concentration (nM) 
Figure 19: Plot of maximum specific mass of a-TTP bound to an artificial endosomal 
lipid mixture with LBPA. Endosomal lipids with LBPA is made up of 50 mol% 
DOpe, 20 mol% DOPE, 5 mol% DOPS, SM and PI and 15 mol% LBPA with a final 
lipid concentration of 2.54 mM Data are representative of four measurements from 
two independent sample injections. 
In protein-ligand interactions, the Kd corresponds to the concentration when 
half of the protein concentration is ligand-bound. Therefore a lower Kd value signifies 
a stronger binding affinity between the protein and ligand. However, in this case, the 
lipid membrane is not the ligand for a-TTP rather it is the location for a-TTP to 
release or retrieve its ligand. Therefore the Kd does not signify half of the 
concentration of a-TTP being occupied, instead, the Kd represents the half the 
maximum possible association of a-TIP to the membrane. In DPI analysis, the 
amount of lipid present is fixed on the sensor chip. However, the amount of protein 
introduced on to the chip is varied. The general trend observed for a-TTP is that as 
protein concentration increases, more protein was bound regardless of lipid 
composition. In Section 1.3, earlier studies proposed that a-TTP associates to 
membranes via its lid helix (a-lO) [35]. Since there are no specific sites on the 
membrane that favour a-TTP's binding to it, when a-TTP is introduced on to the 
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sensor chip, the way it recognizes and binds to the membrane surface is similar 
regardless of where it lands on a homogeneous sample of adsorbed vesicles. 
However, the lower Kd value seen with the LBPA-containing lipids is an indication of 
a stronger binding affinity between a-TTP and LBPA-containing lipids. This means 
that in comparison with the other lipid mixtures, a lesser amount of protein was 
required to saturate the lipid surface on the sensor chip, given that the lipid surface 
area available to the protein is limited on a sensor chip. 
The Bmax value represents the maximum specific mass of protein bound to the 
sensor chip. For the DOPC:DOPS lipid mixture, the Bmax obtained from the DPI 
measurement was 1.98 ± 0.143 ng/mm2. This means that approximately 1.98 ng of a-
TTP are bound to one mm2 area of the sensor chip. It appears that the Bmax value 
decreases slightly with the endosomallipids without LBPA and with LBPA, 1.42 ± 
0.176 ng/mm2 and 1.24 ± 0.096 ng/mm2 respectively, when compared to the 
DOPC:DOPS lipid mixture. This means that the amount of bound protein decreased 
with the inclusion of endosomal lipids. The reduced amount of protein bound to the 
sensor chip might be explained with reference to the increased average thickness 
bilayer as seen in Table 3. It was described in Section 3.2.1 that the endosomallipids 
seem to possess a thicker bilayer. This increased bilayer thickness was rationalize by 
the presence of non-bilayer lipids and the presence of partially uncollapsed vesicles. 
Consequently, this implies that the surface of the lipid bilayer is no longer 
homogenous. As a result, there are fewer binding sites available for a-TTP to bind to. 
The maximum specific mass of a-TTP did not vary significantly between endosomal 
lipids without LBPA (1.42 ± 0.176 ng/mm2) and endosomallipids with LBPA (1.24 ± 
0.096 ng/lllm2) . However the decrease in Kd for endosomal lipids with LBPA 
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indicates a stronger affinity of the protein to the lipid mixture, suggesting a possible 
role of LBP A in a-TTP binding to lipid membranes. 
3.3 Investigation of a-TTP-Lipid Membrane Interactions Using Vesicle Binding 
Assay at Physiological pH Conditions 
The examination of 0,-TTP interactions with lipid membranes usmg DPI 
suggests that LBPA increases the affmity of 0,-TTP binding to membranes. However, 
this does not discriminate whether a-TTP binding to membranes is based on its 
affinity for LBPA itself or the curvature effect generated by LBPA in membranes. 
Thus, the vesicle binding assay was employed to investigate the binding of a-TTP to 
lipid vesicles mimicking curved membranes. It is important to emphasize here that 
the vesicle binding assay utilized in this project is a semi-quantitative measure of 
binding affinity as compared to the DPI analysis. It is used mainly as a 
complementary technique to DPI to observe binding trends. This is due to the nature 
of the assay which caused large errors to occur especially when LUVs were 
employed, since the amount of protein bound to LUVs is less than to SUVs of the 
same lipid composition. As a result, the Kd and Bmax values were not extracted from 
the binding curves except in a few instances where the errors are minimal. All 
binding curves were plotted using GraphPad Prism. The vesicle binding data could 
not be treated using data weighting methods, possibly suggesting that the assumption 
of 'one-site binding' is not accurate for this system. 
In this assay, lipid-bound proteins were separated from free proteins using a 
centrifugal filter. Both lipid-bound and free protein fractions were then analyzed by 
SDS-PAGE. Band intensities were evaluated by densitometry and the values for 
lipid-bound fractions were fit to a binding saturation curve to show the binding trend. 
For each assay, lipid-bound fractions were· normalized against the highest lipid 
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concentration fraction, which represents the maximum amount of bound protein in 
any particular instance. On the other hand, the free protein fractions can also be used 
to show binding trends (Appendix I). In this case, the curves are the mirror-images 
of the lipid-bound fractions and the results generally show similar binding trends. 
Here, the free protein fractions were normalized against the amount of protein 
recovered when no lipid was present, which is taken as the total amount of free 
protein and fitted to a one phase exponential decay curve. 
It is also noteworthy that the densitometry values can be assessed by an 
alternative method. In this case, the lipid-bound fractions are calculated from the free 
protein fractions [91-92]. Based on Feng et al. 's work, lipid-bound fractions were 
determined by (1 - PdPt) [91]. Prrepresents the free protein recovered when lipid was 
present, while Pt is the free protein recovered when no lipid was present. Therefore Pt 
represents the total amount of free protein. The lipid-bound fractions are represented 
as PblPt where Pb is the amount of lipid-bound protein [91]. The data was fit to a one-
site saturation binding curve. Again, the results obtained from this manner of data 
analysis are closely similar to those obtained from the previously mentioned analysis 
(Appendix II). The use of two different data analysis methods reveals that the results 
obtained from the vesicle binding assay are qualitatively reproducible. This means 
that either the free protein or the lipid-bound fractions can be used to show binding 
trends. However, it should be mentioned that a discrepancy was observed when low 
pH conditions were introduced into this assay that affected both the free and lipid-
bound protein fractions. This discrepancy is due to the insolubility of the lipid and/or 
protein at low pH conditions rather than the assay itself and will be discussed further 
in Section 3.4.2. For clarification and consistency, the data analysis method that 
measures the lipid-bound fractions directly will be used in the following sections. 
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3.3.1 Effect of lipid composition on u-TTP's interaction with lipid vesicles 
Prior to employing the vesicle binding assay to investigate u-TTP's binding to 
lipid membranes, the assay was first examined with DOPC:DOPS lipid vesicles. 
DOPC:DOPS vesicles (200 run in diameter) of increasing concentration were 
incubated with u-TTP at a fixed concentration. The results obtained showed that u-
TTP does bind to DOPC:DOPS vesicles. When DOPC:DOPS vesicles were replaced 
with vesicles containing endosomal lipids without LBPA, the amount of lipid-bound-
u-TTP was comparable to that with DOPC:DOPS lipids. However, a further increase 
in the amount of lipid-bound protein was observed when LBP A was present (Figure 
20). 
The SDS-PAGE analysis of the free and bound protein fractions clearly 
demonstrates this distinction in the binding of u-TIP to lipid vesicles based on their 
composition (Figure 20 A-C). The trend observed here is that more protein is 
retained in the lipid-bound fractions as lipid concentration increases and more so 
when LBP A is present. When the densitometry values for lipid-bound fractions were 
plotted against LUV concentration, a similar trend was observed (Figure 20 D). 
Interestingly, these findings correspond to those observed in the DPI analysis, further 
supporting the fact that LBPA does have an effect on u-TTP's binding to membranes. 
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Figure 20: Effect of lipid composition on a-TTP binding to lipid vesicles at pH 7.5. 
SDS-PAGE analysis offree and bound a-TTP to 200 nm LUVs of (A) DOPC:DOPS, 
(B) endosomal lipids without LBPA and (C) endosomal lipids with LBPA present. 
Binding curves plotted from lipid-bound fractions (D). Data are taken from three 
separate measurements. 
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Figure 21: BSA binding to 200 nm LUVs at pH 7.5. SDS-PAGE analysis offree and 
bound BSA to 200 nm vesicles of (A) DOPC:DOPS, (B) endosomal lipids without 
LBP A and (C) endosomal lipids with LBPA present. Binding curves plotted from 
lipid-bound fractions (D). Data are from one measurement. 
As a control measure, another soluble protein, bovine serum albumin (BSA) 
was used in this assay under similar conditions. In general, BSA did not demonstrate 
any specific binding toward all three lipid systems used here (Figure 2tD). However, 
it should be noted that some non-specific binding occurs between BSA and the lipid 
mixtures as observed in the weaker bands present in the lipid-bound fraction for all 
three lipid mixtures (Figure 2t A-C). It was also noticed that more BSA were 
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present in the lipid-bound fractions when endosomal lipids were used. Why this 
occurs remains unanswered. The main deduction from this study was to show that the 
association of a-TTP to membranes is not a result of non-specific binding of the 
protein to lipids or to the centrifugal filter. It also excludes the notion that a-TTP may 
be trapped by the lipid vesicles. Instead, this analysis reveals that a-TTP possesses 
the ability to bind to lipid membranes and this ability is specifically influenced by 
lipid composition. 
3.3.2 Effect of membrane curvature on u-TTP binding to lipid vesicles 
The next objective was to investigate the effect of bilayer curvature on a-
TTP's binding to membranes. Under similar conditions, a-TTP was incubated with 
SUVs for all three lipid systems. SUVs produced by probe sonication generally yield 
vesicles about 25 - 30 nm in diameter [94]. 
From the results seen in Figure 22, it is evident that the amount of a-TTP 
bound to all three lipid systems is similar. This is further substantiated by the Bmax 
values which represent the maximum amount of bound protein for each lipid system, 
as shown in Table 4. This implies that the amount of a-TTP bound to SUVs is the 
same regardless of the lipid composition of the vesicles. However the Kd values from 
these curves, as shown in Table 5, reveal that a-TTP has a higher binding affinity to 
endosomal lipids with LBP A. This suggests that LBP A plays a role in a-TTP binding 
to lipid membranes even in SUVs. However, comparing between the binding curves, 
the increased amount of a-TTP bound to SUVs compared to LUVs cannot be 
excluded here. This suggests that membrane curvature plays a significant role in a-
TTP's binding to membranes. These observations are in line with recent findings that 
the ligand transfer rate by a-TTP is greater with SUVs containing only PC compared 
to LUVs [38]. Therefore, a-TTP's preference to bind to highly curved membrane 
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surfaces, regardless of lipid composition, as seen here is consistent with the higher 
ligand transfer rate seen with SUVs versus LUVs. However, it is still not possible to 
conclude at this point that no specific interaction exists between a-TTP and LBP A. 
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Figure 22: a-TTP binding to SUVs at pH 7.5. SDS-P A GE analysis of free and bound 
a-TTP to SUVs of (A) DOPC: DOPS, (B) endosomallipids without LBPA and (C) 
endosomal lipids with LBPA. Binding curves plotted from lipid-bound fractions (D). 
Data are from three independent measurements. 
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Lipid system Bmax (Bound protein fraction) 
DOPC:DOPS 1.03 ± 0.053 
Endosomallipids without LBPA 1.13 ± 0.051 
Endosomallipids with LBP A 1.08 ± 0.031 
Table 4: Bmaxvalues obtained from (1-TTP-SUV binding curves at pH 7.5. 
Lipid system Kd(mM) 
DOPC:DOPS 0.118 ± 0.025 
Endosomallipids without LBP A 0.090 ± 0.018 
Endosomallipids with LBPA 0.043 ± 0.007 
Table 5: Kdvalues obtained from (1-TTP-SUV binding curves at pH 7.5. 
To show that a-TTP's binding to SUVs was not a result of non-specific 
binding, BSA was tested in the similar fashion. Results are shown in Figure 23. No 
specific binding was observed between BSA and the three lipid systems. However, 
the presence of the weaker bands in the lipid-bound fractions again indicates that non-
specific binding exists to some degree to the lipids. On the whole, the use of BSA in 
this study further supports a-TTP's preference to bind to highly curved membrane 
surfaces. 
The results so far reveal that more a-TIP is bound to larger vesicles when 
LBP A is present, but the LBP A effect is reduced or insignificant when small vesicles 
are used instead. The next aim was to investigate the binding of a-TTP to larger 
vesicles; in this case, LUVs of 400 nm in diameter were used, which are double the 
diameter of the 200 nm LUVs. Since DOPC:DOPS vesicles had already been used to 
show that a-TTP was able to bind to membranes in this assays, this lipid mixture was 
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not included in the following trial. Moreover, since a similar amount of u-TTP bound 
to endosomal lipids without LBPA compared to DOPC:DOPS vesicles, only the 
endosomallipids with and without LBP A were examined for the 400 nm LUV s. 
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Figllre 23: BSA binding to SUVs at pH 7.5. SDS-PAGE analysis offree and bound 
BSA to SUVs of (A) DOPC: DOPS, (B) endosomal lipids without LBPA and (C) 
endosomal lipids with LBP A present. Binding curves plotted from lipid-bound 
fractions (D). Data are from one measurement. 
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Figure 24: a-TTP binding to 400 nm LUVs at pH 7.5. SDS-PAGE analysis offree 
and bound a-TTP to LUVs of (A) endosomal Upids without LBPA and (B) endosomal 
lipids with LBP A. Binding curves plotted from lipid-bound fractions (e). Data are 
from three independent measurements. 
Results from the analysis showed a similar pattern as seen with the 200 nm 
LUVs - more a-TTP were bound to endosomal lipids when LBPA was present 
(Figure 24). Since the main focus is on the endosomal lipids with LBPA present, a 
comparison of a-TTP' s binding trend to LBP A -containing vesicles based on vesicle 
size is shown in Figure 25. 
59 
1.2 
--= 
.S; 1.0 
... 
CJ 
c:: 
J:::: 0.8 
--
= 
'a:: 0.6 
... 
e 
Q., 0.4 
't:I 
=  0.2 Q 
~ 
• 
O.O ..... -----r----~---""T'"-
0.0 0.5 1.0 1.5 
[SUV/LUV] mM 
- SUVs 
-e- LUVs (200 run) 
-- LUVs (400 run) 
Figure 25: Curvature effect on a-TTP binding to membranes at pH 7.5. Shown here 
is a greater amount of a-TTP bound to SUVs containing endosomal lipids with LBP A 
compared to 200 and 400 nm LUVs of similar lipid composition. Data are from three 
independent measurements. 
Comparison between the Kd and Bmax values obtained from Figure 25 are 
shown in Table 6. The Bmax values are similar between SUVs and LUVs implying 
that the maximum amount of bound protein is the same for all three types of vesicles. 
It should be noted that the Bmax values are greater than one possibly due some data 
points that exceeds the fraction of the highest lipid concentration. The Kd values for 
both 200 and 400 run LUVs are similar. However, the Kd value for SUVs is 
approximately ten times less than those of the LUV s, indicating a stronger affinity 
between u-TTP and SUV s. This evidently shows that u-TTP binding to membranes is 
influenced by the curvature of the membrane structure to which it binds. 
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Endosomal Lipids with LBPA Kd(mM) Bmax (Bound protein fraction) 
SUVs 0.043 ± 0.007 1.08 ± 0.031 
LUVs (200 nm) 0.581 ± 0.134 1.21 ± 0.119 
LUVs (400 nm) 0.463 ± 0.103 1.05 ± 0.103 
Table 6: Comparison between Kd and Bmax values for a-TTP bound to SUVs, LUVs of 
200 nm and 400 nm diameters. 
The vesicle binding assay results obtained so far clearly shows that a-TTP 
prefers to bind to a highly curved membrane surface as opposed to a flatter one. The 
degree of curvature of a lipid vesicle is proportional to lIR, where R is the diameter of 
the vesicle [95]. Therefore, the spontaneous curvature of a 25 nm SUV is greater than 
a 200 and 400 nm LUV by eight and sixteen times respectively. This means that 
when a-TTP approaches a LUV of a diameter ranging between 200 and 400 nm 
compared to a 25 nm SUV, the surface of the LUV would appear essentially flat 
rather than curved as with the SUV (Figure 26). 
a.-TTP 
gOo 
oB 
a.-TIP 
Figure 26: An illustration to show how a-TTP views a SUV versus a LUV or flat 
bilayer. a-TTP sees the SUV surface as highly curved with more free space within the 
lipid head-groups allowing easier access to bind. In contrast, a-TTP sees the LUV 
andflat bilayers as aflat surface. Shown here isjust the representation of lipid head-
groups of the outer monolayer to which a-TTP associates. 
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In the introductory section, it was shown that LBP A plays a role in generating 
curvature in lipid membranes. Taking this into account and a-TTP's preference to 
bind to highly curved membrane surfaces indicates that a-TTP binding to LBP A-
containing LUV s is a result of local curvature generated by LBP A. The ability of 
LBP A to form multivesicular structures, which also means generating local curvature 
within a liposome, is dependent upon a low pH environment [45]. However, in this 
case, an enhanced binding is observed despite the fact that the pH conditions were 
near neutra1. A recent study investigating the morphology of LBP A vesicles showed 
that hydrated LBP A vesicles at neutral pH formed non-spherical vesicles with small 
budlike protrusions [90]. This may suggest that the presence of LBPA within the 
vesicle causes the lipid bilayer to want to bud and form multi vesicular structures but 
is unable to do so due to the neutral pH. The uneven bilayer surface and budlike 
protrusions (both indicative of higher curvature membrane morphologies) of LBPA-
containing LUVs at neutral pH may then explain the increased amount of a-TTP 
bound to these vesicles. It should be mentioned that in the same study, extruded 
LBPA vesicles formed well-rounded vesicles at neutral pH [90]. However it should 
also be noted that the methodology in LUV preparation and number of extrusion 
times used in this project differs from those used in Frederick et al.'s work. This may 
mean that even though extruded LBPA-containing vesicles produce well-rounded 
vesicles at neutral pH, the amount of time for them to remain stable in this spherical 
shape may vary with the previously mentioned factors. Another factor to be 
considered is that in Frederick et al.'s work, vesicles were made of 100 mol% LBPA 
as opposed to our vesicles which contain only 15 mol% LBP A; therefore any local 
curvature effect of LBPA will be reduced. In the situation where LBPA-containing 
lipids are forced into a flat bilayer such as during DPI analysis, it is uncertain whether 
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the membrane surface is irregular or whether any budlike protrusions exist. If truly 
budlike protrusions exist, such structures may be able to enhance the binding of a-
TTP to the LBPA-containing bilayer. 
An alternative rationalization to account for the increase in a-TTP binding to 
LBPA-containing LUVs and flat bilayers is based on curvature stress. The concept of 
peripheral proteins binding to lipid membranes dictated by curvature stress in the lipid 
bilayer is one that cannot be dismissed [88]. Two examples of proteins that are 
regulated this way are the CTP (cytidine triphosphate ):phosphocholine 
cytidyltransferase (CT) and leader peptidase [96-98]. While CT catalyzes the key step 
in phosphatidylcholine synthesis, leader peptidase cleaves signal peptides from 
translocated precursor proteins. Both proteins have been shown to preferentially 
interact with membranes containing the non-bilayer lipid DOPE as opposed to just 
DOPe. In section 3.2.1 it was discussed that the presence of non-bilayer lipids such 
as DOPE increases curvature stress within the bilayer. In addition, the smaller head-
group of DOPE results in exposed hydrophobic sites, also known as insertion sites 
[96-98]. It was then proposed that the presence of the insertion sites allows easier 
access of peripheral proteins to bind to the bilayer, especially those that bind via 
hydrophobic interactions. The binding of peripheral proteins to membranes aids in 
relieving curvature stress by allowing the lipids that are within close proximity of the 
protein to splay apart [96]. It should be mentioned that at present there are many 
terms used to describe the role of lipid regulation of protein function. The description 
used here is curvature stress, but a few other examples include lipid packing stress, 
lateral pressure profile and bilayer deformation energy [99]. At the moment, there is 
no agreement as to which is the correct phenomenon to be used in any description of 
peripheral protein binding to membranes. 
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Since LBP A does not normally form lamellar shaped lipid bilayers, it is not 
surprising that its presence will cause curvature stress within a lipid bilayer. Whether 
LBP A forms negative or positive curvature is yet to be determined. However there is 
evidence that shows LBPA is able to induce some kind of curvature as mentioned 
earlier, with the formation of bud like protrusions at neutral pH and the multivesicular 
liposomes at pH 5.5 [90,45]. Due to the curvature forming properties by LBPA, its 
presence within a lipid bilayer - in this case the extruded vesicles that are well 
rounded without any protrusions and the flat bilayer on the sensor chip - will result in 
curvature stress. As there are no concrete measurements at present to state whether 
LBP A has a smaller or larger head-group, we cannot be certain that LBP A has the 
same effect as DOPE - the formation of insertion sites allowing easier access of 
proteins to the membrane. Whether LBPA induces positive or negative curvature, 
forcing it into a bilayer structure, will no doubt produce some form of curvature 
stress. One method for the membrane to relieve this stress is through the binding of 
proteins. Previously, it was mentioned that the insertion of a peripheral protein into 
the bilayer causes the surrounding lipids to splay apart. This slight change in 
orientation may aid in relieving the build-up of stress within the bilayer (Figure 27) 
[95]. This explanation may explain the results obtained from DPI analysis which 
showed a two-fold increase in binding affinity when LBPA was present, albeit in this 
case in a flat lipid surface. Also, if the extruded LBPA-LUVs remain in a well-
rounded shape without any budding surfaces being formed [90], then the above 
description can be used here. It should be noted that even though DOPE is a non-
bilayer lipid, yet its curvature effect does not appear to influence a-TTP binding to 
membranes. This could simply mean that the 20 mol% of DOPE present in 
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endosomal lipids IS insufficient to have a large effect on a-TTP binding to 
membranes. 
a-TIP 
a -TIP 
Figure 27: An illustration of the rationalization of how a-TTP binding to membranes 
may be influenced by LBPA. The presence of the non-bilayer LBPA (shaded lipids) 
within the bilayer results in increase curvature stress (shown as the black arrows). 
Binding of a-TIP to the stressed bilayer helps to relieve the curvature stress by 
splaying apart the neighbouring lipids. 
The increased binding affinity of a-TTP to SUVs can be explained as follows. 
SUV s are highly curved vesicles that have a higher curvature stress [100-101] which 
is reflected by their tendency to fuse over time. They also contain more free space 
between the lipid head-groups of the outer monolayer. This available free space is 
analogous to the insertion sites described previously. Both the available free space 
between the head-groups which allows easier access and the higher curvature stress 
may account for the increased affinity of a-TTP for SUV s. 
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3.4 pH Effect on a-TTP's Interactions to Lipid Membranes 
Up to now, the discussion has concerned measurements that were conducted 
under physiological pH conditions. However, in both Matsuo and Kobayashi et aI.'s 
work, it was apparent that low pH conditions (pH 5.5) were required for LBPA to 
form multivesicular liposomes and to manifest its fusogenic properties [44-45]. 
Therefore, it was important to investigate the effect of low pH conditions on the 
association of TTP with lipid membranes. 
3.4.1 Investigation of a-TTP's solubility at low pH conditions 
u-TTP possesses an isoelectric point (PI) of approximately 5.1 [30]. This 
value is close to the optimal pH value (pH 5.5) for LBPA to produce multivesicular 
morphology. Since pH 5.5 is close to u-TTP' s pI, we were concerned that u-TTP may 
precipitate at this pH level. Therefore it was important to investigate the stability of 
u-TIP under this condition or at least determine the lowest pH that still allows us to 
perform the assay with a soluble protein. A simple test was done by incubating u-
TTP in 2-(N-morpholino)ethanesulphonic acid (MES) buffer at different pH values of 
6.5,6.0 and 5.5. MES was chosen as it has a pKa value of 6.15, which is suitable to 
buffer the pH ranges being tested without the need of using different buffer systems. 
A small volume from each mixture was removed and tested for protein concentration 
using the Bradford assay. Prior to that, the mixture was centrifuged to remove any 
precipitates. Protein concentration was measured at intervals of one hour for up to 
three hours. A time span of three hours was chosen as it provides sufficient time to 
perform a vesicle binding assay. Generally, a vesicle binding assay for one replicate 
requires about 1.5 to 2 hours. The aim of this test was to observe any decline in 
protein concentration over the three hour period which would indicate that the protein 
is precipitating. This test was conducted at room temperature. Initially, the 
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experiment was done with 200 mM of potassium chloride (Kel) present. However, 
with the protein in the pH 6.0 and 5.5 buffers, a gradual decline in protein 
concentration was observed. Moreover, with pH 5.5, an approximately 50 % 
reduction was seen at the initial measurement (time = 0 hour), signifying that the 
protein was falling out of solution as soon as it came into contact with the buffer 
solution (Figure 28 A). Although the pH of the buffer had a value of 5.5, after the 
addition of the protein (in elution buffer at pH 7.5), the mixture had an overall pH of 
5.7. Therefore, the final pH value will be reported as 5.7. Since a-TTP is purified in 
Tris(hydroxymethyl)aminomethane (Tris) buffer, as a control measure, the test was 
also conducted with a-TTP in Tris buffer at pH 7.5. a-TTP's solubility was plotted as 
optical density (O.D.) values at absorbance of 595 nm against time. The protein 
concentrations from the O.D. values were determined and it should be noted that the 
concentrations corresponding to the O.D. values ranging between 0.4 and 0.5 is 
comparable to the initial protein concentration added to the mixture. 
Since salt plays a role in protein solubility, the next step was to conduct the 
same analysis with only the pH 6.0 and 5.7 conditions without the presence of salt. 
Interestingly, the protein concentration at both pH values was maintained over the 
three hour period (Figure 28 B). However to maintain consistency with the buffer 
system used in the vesicle binding assay at neutral pH, salt was added back to the 
buffer system at pH 5.7 but at a lower concentration of 100 mM. This time no 
reduction was observed in the protein concentration (Figure 28 C). Having 
established a-TTP's stability at pH 5.7 with this buffer condition, the investigation of 
the effect of pH on a-TTP binding to membranes was able to proceed. 
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Figure 28: Effect of pH on a-TTP solubility. a-TTP in MES buffer with 200 mM KCl 
at different pH ranges except for pH 7.5 which uses Tris buffer (A) . a-TTP in MES 
buffer without KCf at pH 6.0 and 5.5 (B). a-TTP in MES buffer at pH 5.5 with 100 
mM KCf (C). All data shown are from single measurements except for (C) which are 
in duplicates. 
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3.4.2 Effect of pH on u-TTP's association to lipid vesicles using the vesicle 
binding assay 
It should be mentioned here that performing the vesicle binding assay at low 
pH conditions had one drawback. It was noted that a white precipitate was visible 
only in the lipid-bound fractions regardless of the type of lipid mixture used. 
However, no precipitate was observed in the fractions when the lipid concentration 
was zero. In addition, there seemed to be an increase in precipitation in the lipid-
bound fractions as lipid concentration increased. An investigation was carried out to 
determine the cause of this precipitation. The assay was fIrst done with just a single 
sample containing the buffer alone. No precipitation was visible, ruling out the idea 
that the buffer solution was the source of the precipitation. In an additional assay, a 
single sample containing lipid (l.5 mM DOPC:DOPS) was introduced into the buffer 
but no protein was added. In this case, the precipitate was visible. From this test, it 
appears that the lipids were precipitating. However, during the actual assay, we 
cannot rule out that the precipitates are protein-free. It is possible that as the lipid 
falls out of solution, any bound-protein may also precipitate along with it. An attempt 
was made to isolate the precipitate and test for proteins, however it was unsuccessful. 
It should be pointed out that during the preparation of the lipid vesicles at pH 5.7, no 
precipitates were observed. Another test was also conducted which involved setting 
aside two samples: one containing the lipid alone and the other containing both the 
lipid' and protein in the buffer and leaving both samples out at room temperature for as 
long as three hours. The idea of this test was to see if any precipitation occurred over 
this time span. After the three hour period no solid deposits were observed in either 
sample, as seen in the lipid-bound fractions. 
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One difference observed in the vesicle binding assay at pH 5.7 compared to 
pH 7.5 was that the centrifugation time (during separation of free protein from bound) 
increased significantly, especially for the higher concentrations of lipids. An assay at 
neutral pH that on average took about 1.5 to 2 hours to complete was now taking 
about 4 hours to complete. This was true for all lipid systems. So far, all the assays 
were centrifuged at room temperature. This did not pose a problem with the neutral 
pH conditions. But with the acidic conditions, as spin time increased, one thing that 
was noticeable was the heat generated within the microfuge. To maintain a stable 
temperature environment, the assays were conducted in a refrigerated microfuge and 
the temperature was maintained at 25°C. When a trial run was conducted using the 
refrigerated microfuge with the endosomal lipids without LBPA (400 nm LUVs), 
interestingly, a significant reduction in the precipitation was observed. However, 
when the remaining lipid systems were used under this new condition, some 
discrepancies were observed - in that the precipitation was seen again but not in all 
trials. Unfortunately, there was no visible trend in the formation of these precipitates. 
One rationale for this precipitation can be explained as follows. As the protein-lipid 
mixture is being centrifuged to separate the free protein from the bound protein, the 
sample mixture is being concentrated, meaning less solvent is available causing the 
lipids and/or proteins to aggregate and fall out of solution. As the lipids and/or 
proteins fall out of solution, the remaining solution takes longer to pass through the 
filter unit, therefore increasing the spin times significantly. Since this occurred only 
at low pH, it is clear that the acidic conditions playa role in this problem. 
70 
Free protein Lipid-bound protein 
[LUV] mM 
o 0.06 0.25 0.75 1.5 o 0.06 0.25 0.75 1.5 
A 
B 
Figure 29: Comparison of vesicle binding assay at acidic conditions with the use of 
refrigerated microfuge (A) in contrast to without the use of it (B). Shown here are a-
TTP bound to endosomal LUVs (400 nm) without LBPA. 
Two significant observations were also made in the SDS-PAGE analysis when 
the assay was conducted in a refrigerated microfuge as opposed to a non-refrigerated 
microfuge. Firstly, there was a significant reduction in the band intensities for the 
free protein fractions, especially when no lipid was present for the non-refrigerated 
microfuge samples. Secondly, the band intensities for the lipid-bound fractions were 
inconsistent with the lipid concentrations for the non-refrigerated microfuge samples. 
It seems that stronger band intensities were observed at lower lipid concentrations as 
opposed to higher ones (Figure 29). 
What is believed to have taken place in both instances can be explained in two 
ways: 1) some protein is lost during the filtration step through non-specific binding to 
the filter unit; 2) protein precipitation is taking place. It is expected that although the 
results show a-TTP is soluble at pH 5.7 for at least three hours (Section 3.4.1), at this 
pH (close to its pI) it has near neutral charge and thus a tendency to become more 
hydrophobic. As a result of this, a-TTP may have a higher preference to stick to 
either lipids or the filter unit. As a consequence of a more hydrophobic protein at pH 
5.7, it also likely that the amount of Triton X -1"00 used for the rinsing step may not be 
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sufficient to remove the non-specifically bound protein from the filter unit. On the 
other hand, protein precipitation may also account for the decreased band intensity for 
the free protein fraction. Based on the following - that the average time of the assay 
was increased to more than three hours and the solubility of (l-TTP was not examined 
for more than three hours - the notion that over time (l-TTP precipitates cannot be 
dismissed. 
To rationalize the decreased intensity of protein bands at higher lipid 
concentrations, recall that lipid precipitation is more prominent at higher 
concentrations as well. The protein is again either non-specifically bound to the filter 
unit or precipitating out along with the lipids. Although the use of the refrigerated 
microfuge did not solve the precipitation problem entirely, it did improve the assay by 
increasing the band intensities for the free protein fraction and also enhanced the band 
intensity trends for the lipid-bound fractions for most of the trials (Figure 29). 
Having discussed the issues faced whilst performing the vesicle binding assay 
at acidic conditions, the results obtained from the assay can now be reviewed. Since 
changing the pH of the buffer solution meant changing the conditions of the assay, 
DOPC:DOPS lipids were included in the SUV and 200 nm LUV measurements at pH 
5.7 as a comparison. a-TTP binding to SUVs at pH 5.7 showed similar results as at 
neutral pH (Figure 30). Regardless of lipid mixtures, (l-TTP bound with similar 
amounts to SUVs. Again, we see that there is no distinction between the association 
of a-TTP and the lipid vesicles based on lipid composition, similar to what was seen 
with the SUVs at neutral pH. For comparison purposes, the binding curves for the 
endosomallipids with LBPA at both pH 7.5 and 5.7 are shown in Figure 31. 
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Figure 30: Binding curves for a-TTP to SUVs of DOPC: DOPS, endosomal lipids 
with and without LBPA at pH 5.7. Data are taken from three separate measurements. 
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Figure 31: Comparison between the binding trends ofa-TTP to SUVs containing 15 
mol% LBPA at neutral and acidic pH conditions. Data are taken from three 
independent measurements. 
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When SUVs were replaced with 200 nm LUVs, comparing all three lipid 
systems at pH 5.7, the binding trend was closely similar, although more protein was 
bound to the DOpe: DOPS lipids (Figure 32). The amount of a-TTP bound to 
Dope:DOPS vesicles at pH 5.7, increased when compared to those at neutral pH 
(Figure 33 A), testifying to the increased hydrophobicity of a-TTP at this pH. This 
increase was also observed for the endosomallipids without LBP A at pH 5.7 (Figure 
33 B). But the amount of protein bound to the endosomal lipids with LBPA did not 
vary significantly compared to pH 7.5 (Figure 33 e). It seems that at pH 5.7 the 
enhancement of a-TTP-vesicle binding by LBP A is diminished in the 200 nm LUV s. 
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Figure 32: u-TTP binding to 200 nm LUVs at pH 5.7. The data are not fitted to a 
one-site binding curve due to large errors present. Data are from three independent 
measurements. 
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Figure 33: Comparison of binding trends between a-TTF and 200 nm LUVs of 
composed of DOPC: DOPS (A), endosomal lipids without LBPA (B) and endosomal 
lipids with LBP A (C) at neutral and acidic conditions. Data are from three 
independent measurements. The data for all three lipid mixtures at pH 5.7 are not 
fitted to a one-site binding curve due to the large errors present. 
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We next performed a similar analysis with the 400 nm LUVs. Only the 
endosomallipids with and without LBPA were used in this study (Figure 34). In this 
case, the amount of protein bound to endosomal lipids without LBP A was reduced. 
However, the endosomal lipids with LBP A still showed similar amount of bound-
protein when compared to the 200 nm LUVs at pH 7.5. 
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Figure 34: a-TTP binding to 400 nm LUVs at pH 5.7. Data are taken from three 
independent measurements. 
The fact that u-TTP binds to SUVs with nearly the same amount at both 
neutral and acidic conditions continues to support the idea that curvature is important 
in its binding. However, the loss of the binding enhancement (possibly due to 
curvature stresses) by LBP A in 200 nrn LUV s at pH 5.7 can be rationalized as 
follows. u-TTP's tendency to be more hydrophobic at acidic conditions compared to 
a neutral environment, may account for the increased binding seen with the 200 nm 
LUV s at pH 5.7. A reduction in the amount of u-TTP bound to the 400 nm LUV s for 
endosomal lipids without LBP A was observed when compared to the 200 run LUV s 
at pH 5.7 (Figure 35). Further investigation is required to confinn whether the 
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reduction in amount of proteins bound to 400 nm endosomal lipids without LBP A at 
pH 5.7 is real or not. 
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Figure 35: Comparison of the binding trends of a.-TTP to 200 and 400 nm endosomal 
LUVs without LBPA at neutral and acidic pH conditions. 200 nm LUVs at pH 5.7 
showed the highest amount of bound-protein. A reduced amount of protein bound to 
the 400 nm LUVs at pH 5.7 is observed. Data are taken from three independent 
measurements. 
Another explanation for the increased affinity of a-TTP to 200 urn LUVs at 
pH 5.7 stems from the fact that vesicles in acidic conditions can undergo physical 
changes [102]. These changes, which include invaginations and budding are 
influenced by vesicle size and lamellarity and have been observed in giant unilamellar 
vesicles (GUYs) [102]. It should be noted that the GUYs used were first prepared at 
neutral pH and then injected into an acidic medium [102] as opposed to the vesicles 
used in this project which are prepared directly in acidic buffer. However, this does 
not exclude the possibility that LUV's may still undergo these physical changes. If 
invaginations and budding are occurring in the LUYs, this would require that highly 
curved membrane surfaces are present, at least transiently. a-TIP' s preference for 
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curvature and the presence of this curved membrane surfaces may account for the 
increased binding to LUVs at pH 5.7. 
A better methodology to investigate the pH effect on a-TTP' s binding to 
membranes is to use LUVs with a pH gradient in the vesicle binding assay. This 
means preparing vesicles with an internal pH of 5.7 but keeping the external 
environment neutral, mimicking the late endosome. It would also be worthwhile to 
examine the binding of a-TTP to membranes using DPI analysis at acidic conditions. 
This could, in principle, show if protein-membrane binding affinity is similar to 
results obtained from the vesicle binding assay, despite the flatness of surface 
adsorbed bilayers in the DPI. One of the objectives of this project was to conduct this 
DPI analysis, however, due to limited stability of a-TTP at low pH and the lipid 
precipitation problems the examination could not be pursued at this time. 
3.5 Structural Effect On a-TTP's Interactions With Lipid Membranes 
So far, all LBPA investigations performed involved the use of the 3, l' 
isoform. Matsuo et al. showed that the 2, 2' isoform of LBPA, which is also believed 
to be the in vivo form, had a higher activity in multi vesicular formation than the 3,3' 
form [45]. For this reason, the final investigation was to study the effect of the 2, 2' -
LBP A on the binding of a-TTP to membranes using the vesicle binding assay. Since 
the 2, 2' -LBPA isoform is a costly lipid, it was only possible to proceed with the 
vesicle binding assay at this time. Moreover, since the effect of LBP A is most 
obvious in LUVs the 2, 2'-LBPA isoform was tested in 400 nm LUVs in both neutral 
and acidic environments. 
The results obtained under neutral conditions showed a significant increase in 
the binding of a-TTP to 400 nm LUV s when 2, 2'-LBP A was present. A comparison 
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can be seen between endosomal lipids without and with LBPA of the two isoform in 
Figure 36. 
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three separate measurements. 
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When similar investigations were conducted under acidic conditions, the 
increased amount of bound-protein as seen for the neutral pH was not visible here. 
Instead, the amount of a-TIP bound to 2, 2' -LBPA LUV s was closely similar to that 
of 3, 1 '-LBPA LUVs (Figure 37). It was expected that a higher amount of a-TTP 
will bind to 2, 2' -LBPA vesicles at lower pH. However, the results in Figure 37 
show otherwise. One explanation stems from Frederick et al. 's work which observed 
that LBPA rapidly hydrolyzes under acidic conditions - within four days after 
rehydration of the vesicles [90]. Whether one form of LBPA has a higher rate of 
hydrolysis compared to another is not known. In addition it has been reported that 
the acyl chains on the 2, 2' position are thermodynamically unstable and can migrate 
to the 3, l' position [45]. This takes place under either basic or acidic conditions 
[103]. This fact may also contribute towards the unchanged binding affinity of a-TTP 
to 2, 2'-LBP A LUV s at pH 5.7 compared to 3, 1'-LBP A. The final explanation could 
also stem from an increased hydrophobic a-TTP as described in the previous section. 
However, the outcome from the investigation at neutral pH is consistent with previous 
reports regarding the 2, 2' -LBP A - that it is able to generate the curvature effect to a 
greater extent. While at this pH level it may not be able to produce multilamellar 
morphology, it may still be able to contribute to curvature stress. The extent of 
curvature stress may be greater than compared to 3, l' -LBPA due to the changes in 
the overall LBP A structure. 
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4. CONCLUSION 
In summary, results from DPI analyses showed that a-TTP binding to 
membranes is greater in the presence of LBP A at physiological pH conditions. 
However, with this methodology, lipid membranes are believed to be flat. Amethod 
vesicle binding assay was then employed to investigate a-TTP binding to membranes 
that are curved. By means of this assay, a-TTP bound to LBPA-containing LUVs 
(200 and 400 nm) with greater affinity, just as was seen with the DPI analysis at 
neutral pH. These results are consistent since the surface of an LUV would appear 
flat to a-TTP as it approaches the membrane. On the other hand, when SUVs 
replaced the LUV s, more protein was bound to the vesicles regardless of whether 
LBP A was present or not. This suggests the importance of membrane curvature in 
influencing a-TTP's association with lipid membranes. These observations are in 
agreement with recent fIndings on the increased ligand transfer rate by a-TTP with 
SUVs containing only PC [38]. The fact that a-TTP binds to flat lipid bilayers to a 
greater extent when LBP A is present implies that a-TTP is able to specifically 
recognize the local curvature generated by LBP A within this bilayers. DOPE which 
is also a curvature-forming lipid does not appear to have the same effect on a-TIP 
binding to membranes, perhaps due to an inherently lesser influence on curvature on a 
per mol lipid basis. 
Consider the localization of a-TTP to late endosomes: the late endosome is a 
dynamic vesicle where constant budding and fusion is taking place due to intracellular 
trafficking. Only in this vesicle, the LBP A content is found to be as high as 15 mol% 
of the total lipid content. LBP A is believed to play an important role in the 
development of the multi vesicular bodies within the late endosomes. It is then 
possible that as LBP A in the limiting membrane of late endosomes forms 
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multivesicular bodies within the lumen of late endosomes, there are specific areas on 
the limiting membrane that develops high surface curvature and/or curvature stress. 
As these factors favour a-TTP binding to membranes, a-TTP then binds to these 
highly curved and stressed regions of the late endosome where it can insert and/or 
retrieve a-tocopherol. Taking into account the location of a-tocopherol within a 
bilayer, the highly negative curved surface signifies more free space between the lipid 
head-groups of the outer monolayer which then allows easier access of a-TTP to its 
ligand. 
Since the internal lumen of late endosomes are acidic (pH 5.5) and this 
condition is vital for the formation of multivesicular bodies by LBP A, the effect of pH 
was also investigated on the binding of a-TTP to membranes. The results obtained 
from the vesicle binding assays showed that pH did not alter the binding of a-TTP to 
SUVs. Whereas with LUVs, the increased binding to only LBPA-containing LUVs 
was diminished more for the 200 nm LUVs compared to the 400 nm LUVs. One 
reason was described which stems from the increased hydrophobicity of a-TTP at pH 
5.7. 
Matsuo et al. showed that the 2, 2' -LBPA had a higher activity in promoting 
multivesicular morphology in contrast to the 3, 3'-LBPA [45]. Therefore the final 
investigation was to examine the effect of this form of LBP A on a-TTP binding to 
membranes using the vesicle binding assay. At neutral pH, the amount of 0-TTP 
bound to 400 nm LUVs containing 2, 2'-LBPA were significantly higher compared to 
3, l' -LBP A. However, at acidic conditions, no significant changes in the protein 
binding were observed between both forms of LBP A. This could possibly be due to 
either the increased hydrophobicity of a-TTP as mentioned above or the instability of 
the 2, 2'-LBPA LUVs as result of hydrolysis ofLBPA or acyl chain migration. The 
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enhanced binding of a-TTP to 2, 2'-LBPA-vesicles at neutral pH should not be 
overlooked. Since this form of LBPA is believed to exist in vivo and produces more 
curvature, the results seen here signify the importance of this LBP A form in a-TTP 
binding to membranes. 
A better method for testing the pH effect of a-TTP binding to membranes 
using the vesicle binding assay involves the use of LUVs with a pH gradient, where 
the internal environment is acidic while the external environment remains neutral. 
This pH gradient appears to be vital for multivesicular formation [45]. Also this pH 
gradient will mimic the late endosome, since only the late endosome lumen is acidic 
while the exterior or cytoplasm is at physiological pH. In addition, using pH gradient 
LUVs will eliminate the problem with a-TTP's increased hydrophobicity at pH 5.7. 
Acidic liposomes can be prepared by using nigericin, an ionophore, which moves 
protons into the LUV when incubated in a low pH buffer [45, 10 1]. The nigericin is 
then removed and the external buffer is replaced with a neutral one. This procedure is 
performed on a PD-1O desalting and buffer exchange column [45]. Furthermore, it 
would also be advantageous to investigate a-TTP binding to lipid membranes at pH 
5.7 employing the DPI method with both the 3, l' and 2, 2'-LBPA as a means of 
comparison with the vesicle binding assay. So far all analyses performed with DPI 
only took into consideration the deposition of mass layers. Information can also be 
extracted from the rates of formation and dissociation of the mass layer, which can be 
conducted in future DPI analyses. 
Since the results obtained from this pro.ject cannot rule out that no specific 
interaction occurs between a-TTP and LBP A, further examination should be 
performed to elucidate this uncertainty. One technique that can be employed here is a 
protein-lipid overlay assay [104]. In this assay, the phospholipid of interest is spotted 
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onto a nitrocellulose membrane at varyIng concentrations. The nitrocellulose 
membrane is then incubated with the protein of interest. If the protein specifically 
interacts with the lipid, then any bound protein on the nitrocellulose membrane can be 
analyzed via immunoblotting [104]. 
It is important to mention that while other factors may contribute to the 
increased binding of u-TTP to LBPA such as charge, the main emphasis in this thesis 
was on the curvature effect generated by LBP A. LBP A is an anionic lipid and 
whether this negative charge influences the binding of u-TTP to LBP A vesicles can 
be explained as follows. Recent study showed that the ligand transfer rates by u-TTP 
to anionic SUVs, such as PS, PI and LBPA, showed no significant difference in the 
transfer rates compared to PC vesicles [38]. Although transfer rates differs from 
binding measurements, in order for u-TTP to transfer its ligand between donor and 
acceptor vesicles, binding must first occur to the donor vesicles to retrieve its ligand 
and then transfer it to the acceptor vesicles. Since the presence of anionic vesicles did 
not influence the transfer rate and therefore the binding of u-TTP to these vesicles, it 
can be deduced that the negative charge does not influence u-TTP binding to lipid 
membranes. For this reason the effect of anionic lipids on u-TTP association to lipid 
membranes was not investigated in this project. 
It has been mentioned previously that LBP A has been proposed to adopt a 
cone shape, but no actual physical measurement has been performed to confirm this 
fact. One control method to determine the effect of cone-shaped lipids on (1-TIP 
binding to lipid membranes is to use an alternative cone-shaped lipid in place of 
LBPA for example DOPE. This investigation has been previously carried out [81], 
whereby lipid mixtures consisting of DOPC and varying amounts of DOPE were 
introduced into the Analight Bi0200. However, the thickness measurements of these 
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bilayers were found to increase as the proportion of DOPE increased, about 18 mn for 
60:40 DOPC:DOPE lipids. This implies that the presence of DOPE influences the 
proper formation of lipid bilayers on the Analight Bi0200 as explained in Section 
3.2.l. Therefore, the binding of a-TTP to these lipids were not able to be 
investigated. Consequently, this control measure was not included in this project. 
It is also noteworthy to emphasize that there is evidence to show LBP A does 
not undergo lateral phase segregation in mixed bilayers of I-palmitoyl-2-01eoyl-
phosphatidylcholine (POPC) and LBP A [105]. This then rules out the notion that 
binding of a-TTP to lipid membranes may be due to the interaction of a-TTP to 
LBP A-enriched microdomains. 
In conclusion, the overall results from this project provide preliminary 
evidence that membrane curvature is an important factor in influencing a-TTP's 
binding to lipid membranes - specifically the local curvature generated by LBP A. 
Recent work by Zhang et al. also supports the role of membrane curvature in a-TTP 
binding to membranes [38]. The consistency in results is promising, however more 
investigations are required at this stage, some of which were described above, to fully 
elucidate the importance ofLBPA to the mechanism of ligand transfer by a-TTP. 
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APPENDIX I: BINDING CURVES FOR u-TTP PLOTTED FROM FREE 
PROTEIN FRACTIONS 
Below is the representation of data analyzed directly from the free protein fractions. 
The free protein fractions were normalized against the amount of protein recovered 
when no lipid was present, which is taken as the total amount of free protein. 
Although this method of data manipulation produces qualitatively similar binding 
trends as those obtained from the lipid-bound fractions, the loss of proteins at low 
acidic conditions in the free protein fractions affected the binding trend. For this 
reason this data analysis was not chosen for the 'Results & Discussion' section. 
Instead it is shown here as alternate method for analyzing the vesicle binding assay 
results. 
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Appendix I Figure 1: Binding curves of a-TTP to 200 nm LUVs of DOPC:DOPS, 
endosomal lipids with and without LBP A at pH 7.5. Data are analysed from the 
free protein fractions and represent three separate measurements. 
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Appendix I Figure 2: Binding curves of a-TTP to SUVs of DOPCDOPS, 
endosomallipids with and without LBPA at pH 7.5. Data are analysed from the 
free protein !i-actions and represent three separate measurements. 
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Appendix I Figure 3: Binding curves of a-TTP to 400 nm LUVs of endosomal 
lipids without LBPA, endosomallipids with 3, J' and 2,2 '-LBPA at pH 7.5. Data 
are analysed from the free protein fractions and represent three separate 
measurements. 
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Appendix I Figure 4: Binding curves of a-TTP to 200 nm LUVs of DOPC:DOPS, 
endosomal lipids with and without LBPA at pH 5.7. Data are analysed from the 
free protein fractions and represent three separate measurements. 
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Appendix I Figure 5: Binding curves of a-TTP to SUVs of DOPC:DOPS, endosomal 
lipids with and without LBP A at pH 5.7. Data are analysed from the free protein 
fractions and represent three separate measurements 
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Appendix I Figure 6: Binding curves of a-TTP to 400 nm LUVs of endosomallipids 
without LBPA, endosomal lipids with 3, l' and 2, 2 '-LBPA at pH 5. 7. Data are 
analysed from the free protein fractions and represent three separate measurements. 
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Appendix I Figure 7: Binding curves of BSA to 200 nm LUVs of DOPC:DOPS, 
endosomallipids with and without LBPA at pH 7.5. Data are analysed from the free 
protein fractions and each point represents one measurement. 
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APPENDIX II: BINDING CURVES FOR a-TTP BOUND FRACTIONS 
ANAL YZED FROM FREE PROTEIN FRACTIONS 
The data from the free protein fractions can also be analyzed in another method [90-
91]. The lipid-bound fractions were determined by (1 - Pf/Pt) [91]. Pfrepresents the 
free protein recovered when lipid was present while Pt is the free protein recovered 
when no lipid was present. Therefore Pt represents the total amount of free protein. 
The lipid-bound fractions are represented as Pb/Pt where Pb is the amount of lipid-
bound protein. Since this analysis involves the free protein fractions, the similar 
explanation describes why this method was not used for the 'Results & Discussion' 
section. 
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Appendix II Figure 1: Binding curves of a-TTP to 200 nm LUVs of DOPCDOPS, 
endosomal lipids with and without LBP A at pH 7.5. Data are analysed from the free 
protein fractions and represent three separate measurements. 
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Appendix II Figure 2: Binding curves ofa-TTP to SUVs ofDOPCDOPS, endosomal 
lipids with and without LBPA at pH 7.5. Data are analysed from the .free protein 
fractions and represent three separate measurements. 
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Appendix II Figure 3: Binding curves of a-TTP to 400 nm LUVs of endosomallipids 
without LBPA, endosomal lipids with 3, l' and 2, 2 '-LBPA at pH 7.5. Data are 
analysed from the free protein fractions and represent three separate measurements. 
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Appendix II Figure 4: Binding curves of a-TTP to 200 nm LUVs of DOPCDOPS, 
endosomal lipids with and without LBP A at pH 5. 7. Data are analysed from the free 
protein fractions and represent three separate measurements. 
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Appendix II Figure 5: Binding curves of a-TTP to SUVs of DOPC:DOPS, endosomal 
lipids with and without LBP A at pH 5.7. Data are analysed from the free protein 
fractions and represent three separate measurements. 
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Appendix II Figure 6: Binding curves of a-TTP to 400 nm LUVs of, endosomallipids 
without LBPA, endosomal lipids with 3, J' and 2, 2 '-LBPA at pH 5.7. Data are 
analysed from the free protein fractions and represent three separate measurements. 
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Appendix I Figure 7: Binding curves of BSA to 200 nm LUVs of DOPCDOPS, 
endosomal lipids with and without LBP A at pH 7.5. Data are analysed from the free 
protein fractions and each point represents one measurement. 
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Appendix I Figure 8: Binding curves of BSA to SUVs of DOPCDOPS, endosomal 
lipids with and without LBPA at pH 7.5. Data are analysed from the free protein 
fractions and each point represents one measurement. 
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